临床癌症研究 27卷 1-8期-LingLab

临床癌症研究 27卷 1-8期

4002 阅读 2021-05-12 10:29:04 上传

以下文章来源于语言学探索

Clin Cancer Res[Jour] AND 27[volume] AND 1[issue]

临床癌症研究 27卷 1期

Combinationswith Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine KinaseSignaling.

与别构SHP2抑制剂TNO155联合阻断受体酪氨酸激酶信号。

Liu C,Lu H, Wang H, Loo A, Zhang X, Yang G, Kowal C, Delach S, Wang Y, Goldoni S,Hastings WD, Wong K, Gao H, Meyer MJ, Moody SE, LaMarche MJ, Engelman JA,Williams JA, Hammerman PS, Abrams TJ, Mohseni M, Caponigro G, Hao HX.

ClinCancer Res. 2021 Jan 1;27(1):342-354.

AnImmune-Related Gene Prognostic Index for Head and Neck Squamous Cell Carcinoma.

头颈部鳞状细胞癌的免疫相关基因预后指标。

ChenY, Li ZY, Zhou GQ, Sun Y.

ClinCancer Res. 2021 Jan 1;27(1):330-341.

Similaritiesin Risk for COVID-19 and Cancer Disparities.

COVID-19风险的相似性和癌症差异。

NewmanLA, Winn RA, Carethers JM.

ClinCancer Res. 2021 Jan 1;27(1):24-27.

Efficacyand Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-lineTreatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma.

Nivolumab联合Ipilimumab与Sunitinib一线治疗晚期肉瘤样肾细胞癌的疗效和安全性比较。

TannirNM, Signoretti S, Choueiri TK, McDermott DF, Motzer RJ, Flaifel A, Pignon JC,Ficial M, Frontera OA, George S, Powles T, Donskov F, Harrison MR, BarthélémyP, Tykodi SS, Kocsis J, Ravaud A, Rodriguez-Cid JR, Pal SK, Murad AM, Ishii Y,Saggi SS, McHenry MB, Rini BI.

ClinCancer Res. 2021 Jan 1;27(1):78-86.

NovelMethylated DNA Markers in the Surveillance of Colorectal Cancer Recurrence.

新型甲基化DNA标记物在大肠癌复发监测中的应用。

Xie H,Mahoney DW, Foote PH, Burger KN, Doering KA, Taylor WR, Then SS, Cao X,McGlinch M, Berger CK, Wu TT, Hubbard JM, Allawi HT, Kaiser MW, Lidgard GP,Ahlquist DA, Kisiel JB.

ClinCancer Res. 2021 Jan 1;27(1):141-149.

SerialCirculating Tumor DNA in Predicting and Monitoring the Effect of NeoadjuvantChemoradiotherapy in Patients with Rectal Cancer: A Prospective MulticenterStudy.

连续循环肿瘤DNA预测和监测直肠癌新辅助放化疗疗效的前瞻性多中心研究。

ZhouJ, Wang C, Lin G, Xiao Y, Jia W, Xiao G, Liu Q, Wu B, Wu A, Qiu H, Zhang F, HuK, Xue H, Shen Z, Wang Z, Han J, Niu B, Xu Y, Yu Z, Yang L.

ClinCancer Res. 2021 Jan 1;27(1):301-310.

ConcurrentDexamethasone Limits the Clinical Benefit of Immune Checkpoint Blockade inGlioblastoma.

同时使用地塞米松限制了胶质母细胞瘤免疫检查点阻断的临床益处。

IorgulescuJB, Gokhale PC, Speranza MC, Eschle BK, Poitras MJ, Wilkens MK, Soroko KM,Chhoeu C, Knott A, Gao Y, Lim-Fat MJ, Baker GJ, Bonal DM, Nguyen QD, Grant GRL,Ligon KL, Sorger PK, Chiocca EA, Anderson AC, Kirschmeier PT, Sharpe AH,Freeman GJ, Reardon DA.

ClinCancer Res. 2021 Jan 1;27(1):276-287.

Developmentand Validation of a Gene Signature Classifier for Consensus Molecular Subtypingof Colorectal Carcinoma in a CLIA-Certified Setting.

在CLIA认证环境下开发和验证大肠癌共有分子分型的基因特征分类器。

MorrisJS, Luthra R, Liu Y, Duose DY, Lee W, Reddy NG, Windham J, Chen H, Tong Z,Zhang B, Wei W, Ganiraju M, Broom BM, Alvarez HA, Mejia A, Veeranki O, RoutbortMJ, Morris VK, Overman MJ, Menter D, Katkhuda R, Wistuba II, Davis JS, KopetzS, Maru DM.

ClinCancer Res. 2021 Jan 1;27(1):120-130.

In-depthClinical and Biological Exploration of DNA Damage Immune Response as aBiomarker for Oxaliplatin Use in Colorectal Cancer.

DNA损伤免疫反应作为奥沙利铂用于结直肠癌的生物标志物的临床和生物学深入探讨。

MallaSB, Fisher DJ, Domingo E, Blake A, Hassanieh S, Redmond KL, Richman SD, YoudellM, Walker SM, Logan GE, Chatzipli A, Amirkhah R, Humphries MP, Craig SG,McDermott U, Seymour MT, Morton DG, Quirke P, West NP, Salto-Tellez M, KennedyRD, Johnston PG, Tomlinson I, Koelzer VH, Campo L, Kaplan RS, Longley DB, LawlerM, Maughan TS, Brown LC, Dunne PD; S:CORT consortium.

ClinCancer Res. 2021 Jan 1;27(1):288-300.

OvercomingMET-Dependent Resistance to Selective RET Inhibition in Patients with RETFusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib.

Selpercatinib联合环唑替尼克服RET融合阳性肺癌患者对选择性RET抑制的MET依赖性耐药性。

RosenEY, Johnson ML, Clifford SE, Somwar R, Kherani JF, Son J, Bertram AA, DavareMA, Gladstone E, Ivanova EV, Henry DN, Kelley EM, Lin M, Milan MSD, Nair BC,Olek EA, Scanlon JE, Vojnic M, Ebata K, Hechtman JF, Li BT, Sholl LM, TaylorBS, Ladanyi M, Jänne PA, Rothenberg SM, Drilon A, Oxnard GR.

ClinCancer Res. 2021 Jan 1;27(1):34-42.

Genomeand Transcriptome Biomarkers of Response to Immune Checkpoint Inhibitors inAdvanced Solid Tumors.

晚期实体瘤对免疫检查点抑制剂反应的基因组和转录组生物标志物。

PenderA, Titmuss E, Pleasance ED, Fan KY, Pearson H, Brown SD, Grisdale CJ, TophamJT, Shen Y, Bonakdar M, Taylor GA, Williamson LM, Mungall KL, Chuah E, MungallAJ, Moore RA, Lavoie JM, Yip S, Lim H, Renouf DJ, Sun S, Holt RA, Jones SJM,Marra MA, Laskin J.

ClinCancer Res. 2021 Jan 1;27(1):202-212.

Subtype-DiscordantPancreatic Ductal Adenocarcinoma Tumors Show Intermediate Clinical andMolecular Characteristics.

亚型不一致的胰腺导管腺癌具有中等的临床和分子特征。

TophamJT, Karasinska JM, Lee MKC, Csizmok V, Williamson LM, Jang GH, Denroche RE,Tsang ES, Kalloger SE, Wong HL, O'Kane GM, Moore RA, Mungall AJ, Notta F, LoreeJM, Wilson JM, Bathe O, Tang PA, Goodwin R, Knox JJ, Gallinger S, Laskin J,Marra MA, Jones SJM, Renouf DJ, Schaeffer DF.

ClinCancer Res. 2021 Jan 1;27(1):150-157.

IntratumoralInjection of Clostridium novyi-NT Spores in Patients with Treatment-refractoryAdvanced Solid Tumors.

难治性晚期实体瘤患者瘤内注射诺维氏梭状芽胞杆菌。

JankuF, Zhang HH, Pezeshki A, Goel S, Murthy R, Wang-Gillam A, Shepard DR, HelgasonT, Masters T, Hong DS, Piha-Paul SA, Karp DD, Klang M, Huang SY, Sakamuri D,Raina A, Torrisi J, Solomon SB, Weissfeld A, Trevino E, DeCrescenzo G, CollinsA, Miller M, Salstrom JL, Korn RL, Zhang L, Saha S, Leontovich AA, Tung D, KreiderB, Varterasian M, Khazaie K, Gounder MM.

ClinCancer Res. 2021 Jan 1;27(1):96-106.

ThreeDistinct Stroma Types in Human Pancreatic Cancer Identified by Image Analysisof Fibroblast Subpopulations and Collagen.

通过对成纤维细胞亚群和胶原的图像分析确定胰腺癌中三种不同的基质类型。

OgawaY, Masugi Y, Abe T, Yamazaki K, Ueno A, Fujii-Nishimura Y, Hori S, Yagi H, AbeY, Kitago M, Sakamoto M.

ClinCancer Res. 2021 Jan 1;27(1):107-119.

GenomicAnalysis of Germline Variation Associated with Survival of Patients withColorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405(Alliance).

CALGB/swog80405（Alliance）中大肠癌化疗加生物制剂患者生存相关种系变异的基因组分析。

InnocentiF, Sibley AB, Patil SA, Etheridge AS, Jiang C, Ou FS, Howell SD, Plummer SJ,Casey G, Bertagnolli MM, McLeod HL, Auman JT, Blanke CD, Furukawa Y, Venook AP,Kubo M, Lenz HJ, Parker JS, Ratain MJ, Owzar K.

ClinCancer Res. 2021 Jan 1;27(1):267-275.

Delvinginto Early-onset Pancreatic Ductal Adenocarcinoma: How Does Age Fit In?

探讨早发性胰腺导管腺癌：年龄如何适应？

TsangES, Topham JT, Karasinska JM, Lee MKC, Williamson LM, Mendis S, Denroche RE,Jang GH, Kalloger SE, Moore RA, Mungall AJ, Bathe OF, Tang PA, Notta F, WilsonJM, Laskin J, O'Kane GM, Knox JJ, Goodwin RA, Loree JM, Jones SJM, Marra MA,Gallinger S, Schaeffer DF, Renouf DJ.

ClinCancer Res. 2021 Jan 1;27(1):246-254.

DesigningEvolutionary-based Interception Strategies to Block the Transition fromPrecursor Phases to Multiple Myeloma.

设计基于进化的拦截策略来阻止从前体阶段到多发性骨髓瘤的转变。

MauraF, Landgren O, Morgan GJ.

ClinCancer Res. 2021 Jan 1;27(1):15-23.

TERTPromoter Mutation Analysis for Blood-Based Diagnosis and Monitoring of Gliomas.

TERT启动子突变分析在胶质瘤血型诊断和监测中的应用。

MuralidharanK, Yekula A, Small JL, Rosh ZS, Kang KM, Wang L, Lau S, Zhang H, Lee H,Bettegowda C, Chicoine MR, Kalkanis SN, Shankar GM, Nahed BV, Curry WT, JonesPS, Cahill DP, Balaj L, Carter BS.

ClinCancer Res. 2021 Jan 1;27(1):169-178.

ComparativeGenomics Reveals Distinct Immune-oncologic Pathways in African American Menwith Prostate Cancer.

比较基因组学揭示了非洲裔美国前列腺癌患者不同的免疫肿瘤学途径。

AwasthiS, Berglund A, Abraham-Miranda J, Rounbehler RJ, Kensler K, Serna A, Vidal A,You S, Freeman MR, Davicioni E, Liu Y, Karnes RJ, Klein EA, Den RB, Trock BJ,Campbell JD, Einstein DJ, Gupta R, Balk S, Lal P, Park JY, Cleveland JL,Rebbeck TR, Freedland SJ, Yamoah K.

ClinCancer Res. 2021 Jan 1;27(1):320-329.

AnImmune Risk Score Predicts Survival of Patients with Acute Myeloid LeukemiaReceiving Chemotherapy.

免疫风险评分预测接受化疗的急性髓细胞白血病患者的生存率。

WangY, Cai YY, Herold T, Nie RC, Zhang Y, Gale RP, Metzeler KH, Zeng Y, Wang SQ,Pan XY, Yang TH, Wu YB, Zhang Q, Wuxiao ZJ, Du X, Liang ZW, Su YZ, Xu JB, WangYQ, Liu ZL, Wu JW, Zhang X, Wu BY, Xiao RZ, Wang SB, Li JY, Chi PD, Zhang QY,Chen SL, Qin ZY, Zhang XM, Zhong N, Hiddemann W, Liu QF, Zhang B, Liang Y.

ClinCancer Res. 2021 Jan 1;27(1):255-266.

SpatiotemporalHeterogeneity in Multiparametric Physiologic MRI Is Associated with PatientOutcomes in IDH-Wildtype Glioblastoma.

IDH野生型胶质母细胞瘤多参数生理MRI时空异质性与患者预后相关。

ParkJE, Kim HS, Kim N, Park SY, Kim YH, Kim JH.

ClinCancer Res. 2021 Jan 1;27(1):237-245.

PhaseI Clinical Trial of Combination Propranolol and Pembrolizumab in LocallyAdvanced and Metastatic Melanoma: Safety, Tolerability, and PreliminaryEvidence of Antitumor Activity.

普萘洛尔和Pembrolizumab联合治疗局部晚期和转移性黑色素瘤的Ⅰ期临床试验：安全性、耐受性和抗肿瘤活性的初步证据。

GandhiS, Pandey MR, Attwood K, Ji W, Witkiewicz AK, Knudsen ES, Allen C, Tario JD,Wallace PK, Cedeno CD, Levis M, Stack S, Funchain P, Drabick JJ, Bucsek MJ,Puzanov I, Mohammadpour H, Repasky EA, Ernstoff MS.

ClinCancer Res. 2021 Jan 1;27(1):87-95.

Open-label,Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody-DrugConjugate, in Patients with Locally Advanced or Metastatic UrothelialCarcinoma.

局部晚期或转移性尿路上皮癌患者RC48-ADC（HER2靶向抗体-药物结合物）的开放标签、多中心、II期研究。

ShengX, Yan X, Wang L, Shi Y, Yao X, Luo H, Shi B, Liu J, He Z, Yu G, Ying J, Han W,Hu C, Ling Y, Chi Z, Cui C, Si L, Fang J, Zhou A, Guo J.

ClinCancer Res. 2021 Jan 1;27(1):43-51.

U.S.Food and Drug Administration: Initial Experience with the Real-Time OncologyReview Program.

美国食品和药物管理局：实时肿瘤学回顾计划的初步经验。

deClaro RA, Gao JJ, Kim T, Kluetz PG, Theoret MR, Beaver JA, Pazdur R.

ClinCancer Res. 2021 Jan 1;27(1):11-14.

ExpandedLow Allele Frequency RAS and BRAF V600E Testing in Metastatic Colorectal Canceras Predictive Biomarkers for Cetuximab in the Randomized CO.17 Trial.

在随机CO.17试验中，转移性结直肠癌中扩增低等位基因频率RAS和BRAF V600E检测作为西妥昔单抗的预测生物标记物。

LoreeJM, Dowers A, Tu D, Jonker DJ, Edelstein DL, Quinn H, Holtrup F, Price T,Zalcberg JR, Moore MJ, Karapetis CS, O'Callaghan CJ, Waring P, Kennecke HF,Hamilton SR, Kopetz S.

ClinCancer Res. 2021 Jan 1;27(1):52-59.

InternationalConsensus Definition of DNA Methylation Subgroups in Juvenile MyelomonocyticLeukemia.

幼年粒单核细胞白血病DNA甲基化亚群的国际共识定义。

SchönungM, Meyer J, Nöllke P, Olshen AB, Hartmann M, Murakami N, Wakamatsu M, Okuno Y,Plass C, Loh ML, Niemeyer CM, Muramatsu H, Flotho C, Stieglitz E, Lipka DB.

ClinCancer Res. 2021 Jan 1;27(1):158-168.

PreclinicalComparison of the Blood-brain barrier Permeability of Osimertinib with OtherEGFR TKIs.

Osimertinib与其他EGFR TKIs血脑屏障通透性的临床前比较。

ColcloughN, Chen K, Johnström P, Strittmatter N, Yan Y, Wrigley GL, Schou M, Goodwin R,Varnäs K, Adua SJ, Zhao M, Nguyen DX, Maglennon G, Barton P, Atkinson J, ZhangL, Janefeldt A, Wilson J, Smith A, Takano A, Arakawa R, Kondrashov M, MalmquistJ, Revunov E, Vazquez-Romero A, Moein MM, Windhorst AD, Karp NA, Finlay MRV,Ward RA, Yates JWT, Smith PD, Farde L, Cheng Z, Cross DAE.

ClinCancer Res. 2021 Jan 1;27(1):189-201.

ACyclin D1-Dependent Transcriptional Program Predicts Clinical Outcome in MantleCell Lymphoma.

细胞周期蛋白D1依赖的转录程序预测套细胞淋巴瘤的临床结局。

DemajoS, Albero R, Clot G, Castellano G, Navarro A, Capdevila C, Enjuanes A, Nadeu F,Giné E, Pinyol M, Jaffe ES, Ott G, Staudt LM, Rosenwald A, Scott DW, Rimsza LM,López-Guillermo A, Beà S, Campo E, Jares P.

ClinCancer Res. 2021 Jan 1;27(1):213-225.

TheLatest on Uveal Melanoma Research and Clinical Trials: Updates from the CureOcular Melanoma (CURE OM) Science Meeting (2019).

葡萄膜黑色素瘤研究和临床试验的最新进展：治愈眼部黑色素瘤（Cure OM）科学会议（2019）的更新。

ChuaV, Mattei J, Han A, Johnston L, LiPira K, Selig SM, Carvajal RD, Aplin AE,Patel SP.

ClinCancer Res. 2021 Jan 1;27(1):28-33.

Detectionof Chemotherapy-resistant Pancreatic Cancer Using a Glycan Biomarker, sTRA.

用糖链生物标记物检测化疗耐药胰腺癌。

Gao C,Wisniewski L, Liu Y, Staal B, Beddows I, Plenker D, Aldakkak M, Hall J, BarnettD, Gouda MK, Allen P, Drake R, Zureikat A, Huang Y, Evans D, Singhi A, BrandRE, Tuveson DA, Tsai S, Haab BB.

ClinCancer Res. 2021 Jan 1;27(1):226-236.

Flumatinibversus Imatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: APhase III, Randomized, Open-label, Multi-center FESTnd Study.

氟马替尼与伊马替尼治疗新诊断慢性期慢性粒细胞白血病：一项III期、随机、开放标签、多中心FESTnd研究。

ZhangL, Meng L, Liu B, Zhang Y, Zhu H, Cui J, Sun A, Hu Y, Jin J, Jiang H, Zhang X,Li Y, Liu L, Zhang W, Liu X, Gu J, Qiao J, Ouyang G, Liu X, Luo J, Jiang M, XieX, Li J, Zhao C, Zhang M, Yang T, Wang J.

ClinCancer Res. 2021 Jan 1;27(1):70-77.

MRIand 18FET-PET Predict Survival Benefit from Bevacizumab Plus Radiotherapy inPatients with Isocitrate Dehydrogenase Wild-type Glioblastoma: Results from theRandomized ARTE Trial.

MRI和18FET-PET预测贝伐单抗联合放疗对异柠檬酸脱氢酶野生型胶质母细胞瘤患者的生存益处：来自随机ARTE试验的结果。

WirschingHG, Roelcke U, Weller J, Hundsberger T, Hottinger AF, von Moos R, Caparrotti F,Conen K, Remonda L, Roth P, Ochsenbein A, Tabatabai G, Weller M.

ClinCancer Res. 2021 Jan 1;27(1):179-188.

BreastCancer Index Predicts Extended Endocrine Benefit to Individualize Selection ofPatients with HR+ Early-stage Breast Cancer for 10 Years of Endocrine Therapy.

乳腺癌指数预测个体化选择HR+早期乳腺癌患者进行10年内分泌治疗的广泛内分泌益处。

NoordhoekI, Treuner K, Putter H, Zhang Y, Wong J, Meershoek-Klein Kranenbarg E, Duijm-deCarpentier M, van de Velde CJH, Schnabel CA, Liefers GJ.

ClinCancer Res. 2021 Jan 1;27(1):311-319.

PhaseI Study of Alvocidib Followed by 7+3 (Cytarabine + Daunorubicin) in NewlyDiagnosed Acute Myeloid Leukemia.

阿伐昔布联合7+3（阿糖胞苷+柔红霉素）治疗新诊断急性髓系白血病的Ⅰ期研究。

ZeidnerJF, Lee DJ, Frattini M, Fine GD, Costas J, Kolibaba K, Anthony SP, Bearss D,Smith BD.

ClinCancer Res. 2021 Jan 1;27(1):60-69.

UsingMachine Learning Algorithms to Predict Immunotherapy Response in Patients with AdvancedMelanoma.

使用机器学习算法预测晚期黑色素瘤患者的免疫治疗反应。

JohannetP, Coudray N, Donnelly DM, Jour G, Illa-Bochaca I, Xia Y, Johnson DB, WhelessL, Patrinely JR, Nomikou S, Rimm DL, Pavlick AC, Weber JS, Zhong J, Tsirigos A,Osman I.

ClinCancer Res. 2021 Jan 1;27(1):131-140.

NewDrug for Chronic Myeloid Leukemia Might Stimulate the Market.

治疗慢性粒细胞白血病的新药可能会刺激市场。

MüllerMC.

ClinCancer Res. 2021 Jan 1;27(1):3-4.

Checkingthe Hippo in Sarcomatoid Renal Cell Carcinoma with Immunotherapy.

肉瘤样肾细胞癌免疫治疗中Hippo的检测。

HwangJK, Agarwal N, Brugarolas J, Zhang T.

ClinCancer Res. 2021 Jan 1;27(1):5-7.

Age isin the Eye of the Beholder: Distinguishing Molecular Signatures in Early-onsetPancreatic Adenocarcinomas.

年龄是旁观者的眼中钉：区分早发性胰腺腺癌的分子特征。

Lou E.

ClinCancer Res. 2021 Jan 1;27(1):8-10.

SelectedArticles from This Issue.

本期精选文章。

[Noauthors listed]

ClinCancer Res. 2021 Jan 1;27(1):1.

Drug-RadiotherapyCombination Trial Developments-Response.

药物-放射治疗联合试验进展。

DeutschE, Chargari C, Weichselbaum RR, Levy A.

Clin CancerRes. 2021 Jan 1;27(1):356.

Drug-RadiotherapyCombination Trial Developments-Letter.

药物-放疗联合试验进展信。

EvansJR, Cuneo KC, Lawrence TS.

ClinCancer Res. 2021 Jan 1;27(1):355.

Correction:Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, HumanPapillomavirus-unrelated Head and Neck Cancer: A Multicenter, Phase II Trial.

更正：新辅助和辅助Pembrolizumab治疗可切除的局部晚期、与人乳头瘤病毒无关的头颈癌：一项多中心、Ⅱ期试验。

UppaluriR, Campbell KM, Egloff AM, Zolkind P, Skidmore ZL, Nussenbaum B, Paniello RC,Rich JT, Jackson R, Pipkorn P, Michel LS, Ley J, Oppelt P, Dunn GP, Barnell EK,Spies NC, Lin T, Li T, Mulder DT, Hanna Y, Cirlan I, Pugh TJ, Mudianto T, RileyR, Zhou L, Jo VY, Stachler MD, Hanna GJ, Kass J, Haddad R, Schoenfeld JD, GjiniE, Lako A, Thorstad W, Gay HA, Daly M, Rodig SJ, Hagemann IS, Kallogjeri D,Piccirillo JF, Chernock RD, Griffith M, Griffith OL, Adkins DR.

ClinCancer Res. 2021 Jan 1;27(1):357.

Correction:Immune Checkpoint Blockade in Combination with Stereotactic Body Radiotherapyin Patients with Metastatic Pancreatic Ductal Adenocarcinoma.

纠正：免疫检查点阻断联合立体定向放射治疗转移性胰腺导管腺癌。

Xie C,Duffy AG, Brar G, Fioravanti S, Mabry-Hrones D, Walker M, Bonilla CM, Wood BJ,Citrin DE, Gil Ramirez EM, Escorcia FE, Redd B, Hernandez JM, Davis JL, GasmiB, Kleiner D, Steinberg SM, Jones JC, Greten TF.

ClinCancer Res. 2021 Jan 1;27(1):358.

Clin Cancer Res[Jour] AND 27[volume] AND 2[issue]

临床癌症研究 27卷 2期

BlockingIL1 Beta Promotes Tumor Regression and Remodeling of the Myeloid Compartment ina Renal Cell Carcinoma Model: Multidimensional Analyses.

阻断IL1β促进肾细胞癌模型中肿瘤消退和髓系室重构：多维分析。

AggenDH, Ager CR, Obradovic AZ, Chowdhury N, Ghasemzadeh A, Mao W, Chaimowitz MG,Lopez-Bujanda ZA, Spina CS, Hawley JE, Dallos MC, Zhang C, Wang V, Li H, GuoXV, Drake CG.

ClinCancer Res. 2021 Jan 15;27(2):608-621.

CirculatingT-cell Immunosenescence in Patients with Advanced Non-small Cell Lung CancerTreated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy.

单药PD-1/PD-L1抑制剂或铂类化疗对晚期非小细胞肺癌患者循环T细胞免疫衰老的影响。

FerraraR, Naigeon M, Auclin E, Duchemann B, Cassard L, Jouniaux JM, Boselli L, GrivelJ, Desnoyer A, Mezquita L, Texier M, Caramella C, Hendriks L, Planchard D,Remon J, Sangaletti S, Proto C, Garassino MC, Soria JC, Marabelle A, Voisin AL,Farhane S, Besse B, Chaput N.

ClinCancer Res. 2021 Jan 15;27(2):492-503.

CharacterizingCDK12-Mutated Prostate Cancers.

CDK12突变前列腺癌的特征。

RescignoP, Gurel B, Pereira R, Crespo M, Rekowski J, Rediti M, Barrero M, Mateo J,Bianchini D, Messina C, Fenor de la Maza MD, Chandran K, Carmichael J, Guo C,Paschalis A, Sharp A, Seed G, Figueiredo I, Lambros M, Miranda S, Ferreira A,Bertan C, Riisnaes R, Porta N, Yuan W, Carreira S, de Bono JS.

ClinCancer Res. 2021 Jan 15;27(2):566-574.

CD19-specificCAR T Cells that Express a PD-1/CD28 Chimeric Switch-Receptor are Effective inPatients with PD-L1-positive B-Cell Lymphoma.

表达PD-1/CD28嵌合开关受体的CD19特异性cart细胞对PD-L1阳性B细胞淋巴瘤有效。

Liu H,Lei W, Zhang C, Yang C, Wei J, Guo Q, Guo X, Chen Z, Lu Y, Young KH, Lu Z, QianW.

ClinCancer Res. 2021 Jan 15;27(2):473-484.

TargetingIsocitrate Dehydrogenase Mutations in Cancer: Emerging Evidence and DivergingStrategies.

癌症中靶向异柠檬酸脱氢酶突变：新的证据和不同的策略。

WaitkusMS, Yan H.

ClinCancer Res. 2021 Jan 15;27(2):383-388.

SebaceousCarcinoma Epidemiology and Genetics: Emerging Concepts and ClinicalImplications for Screening, Prevention, and Treatment.

皮脂腺癌流行病学和遗传学：筛查、预防和治疗的新概念和临床意义。

SargenMR, Starrett GJ, Engels EA, Cahoon EK, Tucker MA, Goldstein AM.

ClinCancer Res. 2021 Jan 15;27(2):389-393.

ExogenousThyroid Hormone Is Associated with Shortened Survival and Upregulation ofHigh-Risk Gene Expression Profiles in Steroid Receptor-Positive Breast Cancers.

外源性甲状腺激素与类固醇受体阳性乳腺癌生存期缩短和高危基因表达谱上调相关。

Wahdan-AlaswadRS, Edgerton SM, Salem H, Kim HM, Tan AC, Finlay-Schultz J, Wellberg EA,Sartorius CA, Jacobsen BM, Haugen BR, Liu B, Thor AD.

ClinCancer Res. 2021 Jan 15;27(2):585-597.

UncoveringClinically Relevant Gene Fusions with Integrated Genomic and TranscriptomicProfiling of Metastatic Cancers.

利用转移性癌症的整合基因组和转录组分析揭示临床相关基因融合。

TsangES, Grisdale CJ, Pleasance E, Topham JT, Mungall K, Reisle C, Choo C, CarreiraM, Bowlby R, Karasinska JM, MacMillan D, Williamson LM, Chuah E, Moore RA,Mungall AJ, Zhao Y, Tessier-Cloutier B, Ng T, Sun S, Lim HJ, Schaeffer DF,Renouf DJ, Yip S, Laskin J, Marra MA, Jones SJM, Loree JM.

ClinCancer Res. 2021 Jan 15;27(2):522-531.

BETInhibition Enhances the Antileukemic Activity of Low-dose Venetoclax in AcuteMyeloid Leukemia.

BET抑制增强了小剂量Venetoclax对急性髓细胞白血病的抗白血病活性。

RamseyHE, Greenwood D, Zhang S, Childress M, Arrate MP, Gorska AE, Fuller L, Zhao Y,Stengel K, Fischer MA, Stubbs MC, Liu PCC, Boyd K, Rathmell JC, Hiebert SW,Savona MR.

ClinCancer Res. 2021 Jan 15;27(2):598-607.

RecurrentHNSCC Harbor an Immunosuppressive Tumor Immune Microenvironment SuggestingSuccessful Tumor Immune Evasion.

复发性HNSCC具有免疫抑制的肿瘤免疫微环境，提示成功的肿瘤免疫逃避。

WatermannC, Pasternack H, Idel C, Ribbat-Idel J, Brägelmann J, Kuppler P, Offermann A,Jonigk D, Kühnel MP, Schröck A, Dreyer E, Rosero C, Nathansen J, Dubrovska A,Tharun L, Kirfel J, Wollenberg B, Perner S, Krupar R.

ClinCancer Res. 2021 Jan 15;27(2):632-644.

HematopoieticStem Cell Transplantation Positively Affects the Natural History of Cancer inNijmegen Breakage Syndrome.

造血干细胞移植对奈梅亨破裂综合征的癌症自然史有积极影响。

Wolska-KusnierzB, Pastorczak A, Fendler W, Wakulinska A, Dembowska-Baginska B,Heropolitanska-Pliszka E, Piątosa B, Pietrucha B, Kałwak K,Ussowicz M, Pieczonka A, Drabko K, Lejman M, Koltan S, Gozdzik J, Styczynski J,Fedorova A, Miakova N, Deripapa E, Kostyuchenko L, Krenova Z, Hlavackova E,Gennery AR, Sykora KW, Ghosh S, Albert MH, Balashov D, Eapen M, Svec P, SeidelMG, Kilic SS, Tomaszewska A, Wiesik-Szewczyk E, Kreins A, Greil J, Buechner J,Lund B, Gregorek H, Chrzanowska K, Mlynarski W.

ClinCancer Res. 2021 Jan 15;27(2):575-584.

CDK12Deficiency and the Immune Microenvironment in Prostate Cancer.

CDK12缺乏与前列腺癌的免疫微环境。

LotanTL, Antonarakis ES.

ClinCancer Res. 2021 Jan 15;27(2):380-382.

NeoadjuvantTherapy for Melanoma: A U.S. Food and Drug Administration-Melanoma ResearchAlliance Public Workshop.

黑色素瘤的新辅助治疗：美国食品和药物管理局黑色素瘤研究联盟公共研讨会。

MuellerKL, Theoret MR, Lemery SJ, Amiri-Kordestani L, Ariyan CE, Atkins MB, Berry DA,Blank CU, DeMichele AM, Forde PM, Ibrahim N, Keegan P, Mitchell TC, Moss RA,Robert C, Sridhara R, Taube JM, Tetzlaff MT, Wargo JA, Flaherty KT, Kaplan MJ,Topalian SL, Ward AF, Hurlbert MS.

ClinCancer Res. 2021 Jan 15;27(2):394-401.

EarlyResponse to First-Line Anti-PD-1 Treatment in Hodgkin Lymphoma: A PET-BasedAnalysis from the Prospective, Randomized Phase II NIVAHL Trial.

霍奇金淋巴瘤一线抗PD-1治疗的早期反应：来自前瞻性随机Ⅱ期NIVAHL试验的PET分析。

VoltinCA, Mettler J, van Heek L, Goergen H, Müller H, Baues C, Keller U, Meissner J,Trautmann-Grill K, Kerkhoff A, Fuchs M, Sasse S, von Tresckow B, Dietlein M,Borchmann P, Engert A, Kobe C, Bröckelmann PJ.

ClinCancer Res. 2021 Jan 15;27(2):402-407.

GenomicAberrations and Late Recurrence in Postmenopausal Women with HormoneReceptor-positive Early Breast Cancer: Results from the SOLE Trial.

绝经后激素受体阳性早期乳腺癌患者的基因组畸变和晚期复发：来自唯一试验的结果。

Guerini-RoccoE, Gray KP, Fumagalli C, Reforgiato MR, Leone I, Rafaniello Raviele P, MunzoneE, Kammler R, Neven P, Hitre E, Jerusalem G, Simoncini E, Gombos A, Deleu I,Karlsson P, Aebi S, Chirgwin J, Di Lauro V, Thompson A, Graas MP, Barber M,Fontaine C, Loibl S, Gavilá J, Kuroi K, Müller B, O'Reilly S, Di Leo A,Goldhirsch A, Viale G, Barberis M, Regan MM, Colleoni M.

ClinCancer Res. 2021 Jan 15;27(2):504-512.

OncolyticHSV Therapy Modulates Vesicular Trafficking Inducing Cisplatin Sensitivity andAntitumor Immunity.

溶瘤HSV治疗可调节囊泡转运诱导顺铂敏感性和抗肿瘤免疫。

HongB, Chapa V, Saini U, Modgil P, Cohn DE, He G, Siddik ZH, Sood AK, Yan Y,Selvendiran K, Pei G, Zhao Z, Yoo JY, Kaur B.

ClinCancer Res. 2021 Jan 15;27(2):542-553.

MutationalLandscape and Tumor Burden Assessed by Cell-free DNA in Diffuse Large B-CellLymphoma in a Population-Based Study.

在一项基于人群的研究中，弥漫性大B细胞淋巴瘤的突变情况和肿瘤负荷由游离DNA评估。

Rivas-DelgadoA, Nadeu F, Enjuanes A, Casanueva-Eliceiry S, Mozas P, Magnano L, Castrejón deAnta N, Rovira J, Dlouhy I, Martín S, Osuna M, Rodríguez S, Simó M, Pinyol M,Baumann T, Beà S, Balagué O, Delgado J, Villamor N, Setoain X, Campo E, Giné E,López-Guillermo A.

ClinCancer Res. 2021 Jan 15;27(2):513-521.

ASelf-Assembling and Disassembling (SADA) Bispecific Antibody (BsAb) Platformfor Curative Two-step Pretargeted Radioimmunotherapy.

一种用于治疗性两步预靶向放射免疫治疗的SADA双特异性抗体（BsAb）平台。

SantichBH, Cheal SM, Ahmed M, McDevitt MR, Ouerfelli O, Yang G, Veach DR, Fung EK,Patel M, Burnes Vargas D, Malik AA, Guo HF, Zanzonico PB, Monette S, Michel AO,Rudin CM, Larson SM, Cheung NK.

ClinCancer Res. 2021 Jan 15;27(2):532-541.

RNAsequencing and Immunohistochemistry Reveal ZFN7 as a Stronger Marker ofSurvival than Molecular Subtypes in G-CIMP-negative Glioblastoma.

RNA测序和免疫组织化学显示ZFN7比G-CIMP阴性胶质母细胞瘤的分子亚型具有更强的生存标志。

Esteve-CodinaA, Alameda F, Carrato C, Pineda E, Arpí O, Martinez-García M, Mallo M, Gut M,Dabad M, Tortosa A, Del Barco S, Capellades J, Puig J, Gallego O, Pujol T,Oleaga L, Gil-Gil M, de Quintana-Schmidt C, Valduvieco I, Martinez-Cardús A,Bellosillo B, Muñoz-Marmol AM, Esteve A, Domenech M, Camins A, Craven-Bartle J,Villa S, Marruecos J, Domenech S, de la Iglesia N, Balana C.

ClinCancer Res. 2021 Jan 15;27(2):645-655.

PhaseI Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patientswith PIK3CA-Mutant Cancers.

Taselisib（一种亚型选择性PI3K抑制剂）在PIK3CA突变癌症患者中的I期篮式研究。

JhaveriK, Chang MT, Juric D, Saura C, Gambardella V, Melnyk A, Patel MR, Ribrag V, MaCX, Aljumaily R, Bedard PL, Sachdev JC, Dunn L, Won H, Bond J, Jones S, SavageHM, Scaltriti M, Wilson TR, Wei MC, Hyman DM.

ClinCancer Res. 2021 Jan 15;27(2):447-459.

APhase Ib Study of Alpelisib or Buparlisib Combined with Tamoxifen PlusGoserelin in Premenopausal Women with HR-Positive HER2-Negative Advanced BreastCancer.

Alpelisib或Buparlisib联合他莫昔芬和Goserelin治疗HR阳性HER2阴性的绝经前晚期乳腺癌的Ib期研究。

Lu YS,Lee KS, Chao TY, Tseng LM, Chitapanarux I, Chen SC, Liu CT, Sohn J, Kim JH,Chang YC, Yang Y, Shotelersuk K, Jung KH, Valenti R, Slader C, Gao M, Park YH.

ClinCancer Res. 2021 Jan 15;27(2):408-417.

PhaseI Study of Lysine-Specific Demethylase 1 Inhibitor, CC-90011, in Patients withAdvanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma.

赖氨酸特异性去甲基酶1抑制剂CC-90011在晚期实体瘤和复发/难治性非霍奇金淋巴瘤患者中的I期研究。

HollebecqueA, Salvagni S, Plummer R, Isambert N, Niccoli P, Capdevila J, Curigliano G,Moreno V, Martin-Romano P, Baudin E, Arias M, Mora S, de Alvaro J, Di MartinoJ, Parra-Palau JL, Sánchez-Pérez T, Aronchik I, Filvaroff EH, Lamba M, NikolovaZ, de Bono JS.

ClinCancer Res. 2021 Jan 15;27(2):438-446.

A NewGeneration of "Magic Bullets" for Molecular Targeting of Cancer.

新一代分子靶向治疗癌症的“灵丹妙药”。

CapalaJ, Kunos CA.

ClinCancer Res. 2021 Jan 15;27(2):377-379.

AlteredGemcitabine and Nab-paclitaxel Scheduling Improves Therapeutic EfficacyCompared with Standard Concurrent Treatment in Preclinical Models of PancreaticCancer.

在胰腺癌临床前模型中，改变吉西他滨和Nab紫杉醇治疗方案与标准同期治疗相比提高了疗效。

WolfeAR, Robb R, Hegazi A, Abushahin L, Yang L, Shyu DL, Trevino JG, Cruz-MonserrateZ, Jacob JR, Palanichamy K, Chakravarti A, Williams TM.

ClinCancer Res. 2021 Jan 15;27(2):554-565.

OX40Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab inPatients With Advanced Solid Tumors.

OX40激动剂BMS-986178单独或联合Nivolumab和/或Ipilimumab治疗晚期实体瘤患者。

GutierrezM, Moreno V, Heinhuis KM, Olszanski AJ, Spreafico A, Ong M, Chu Q, Carvajal RD,Trigo J, De Olza MO, Provencio M, De Vos FY, De Braud F, Leong S, Lathers D,Wang R, Ravindran P, Feng Y, Aanur P, Melero I.

ClinCancer Res. 2021 Jan 15;27(2):460-472.

SequentialProstate Magnetic Resonance Imaging in Newly Diagnosed High-risk ProstateCancer Treated with Neoadjuvant Enzalutamide is Predictive of TherapeuticResponse.

序贯前列腺磁共振成像对新辅助治疗的高危前列腺癌的疗效有预测作用。

KarzaiF, Walker SM, Wilkinson S, Madan RA, Shih JH, Merino MJ, Harmon SA, VanderWeeleDJ, Cordes LM, Carrabba NV, Bright JR, Terrigino NT, Chun G, Bilusic M,Couvillon A, Hankin A, Williams MN, Lis RT, Ye H, Choyke PL, Gulley JL,Sowalsky AG, Turkbey B, Pinto PA, Dahut WL.

ClinCancer Res. 2021 Jan 15;27(2):429-437.

Early3+3 Trial Dose-Escalation Phase I Clinical Trial Design and Suitability forImmune Checkpoint Inhibitors.

早期3+3试验剂量递增I期临床试验设计和免疫检查点抑制剂的适用性。

RahmaOE, Reuss JE, Giobbie-Hurder A, Shoja E Razavi G, Abu-Shawer O, Mehra P, GuptaS, Simon R, Khleif SN.

ClinCancer Res. 2021 Jan 15;27(2):485-491.

PhaseIb Study of Ribociclib plus Fulvestrant and Ribociclib plus Fulvestrant plusPI3K Inhibitor (Alpelisib or Buparlisib) for HR+ Advanced Breast Cancer.

Ribociclib加Fulvestrant和Ribociclib加Fulvestrant加PI3K抑制剂（Alpelisib或Buparlisib）治疗HR+晚期乳腺癌的Ib期研究。

TolaneySM, Im YH, Calvo E, Lu YS, Hamilton E, Forero-Torres A, Bachelot T, Maur M,Fasolo A, Tiedt R, Nardi L, Stammberger U, Abdelhady AM, Ruan S, Lee SC.

ClinCancer Res. 2021 Jan 15;27(2):418-428.

Settingthe Pick: Can PI3K Inhibitors Circumvent CDK4/6 Inhibitor Resistance?

设置选择：PI3K抑制剂能否绕过CDK4/6抑制剂的耐药性？

ClarkAS, Makhlin I, DeMichele A.

ClinCancer Res. 2021 Jan 15;27(2):371-373.

Developmentof Highly Optimized Antibody-Drug Conjugates against CD33 and CD123 for AcuteMyeloid Leukemia.

抗急性髓细胞白血病CD33和CD123抗体药物结合物的优化研究。

HanYC, Kahler J, Piché-Nicholas N, Hu W, Thibault S, Jiang F, Leal M, KatragaddaM, Maderna A, Dushin R, Prashad N, Charati MB, Clark T, Tumey LN, Tan X,Giannakou A, Rosfjord E, Gerber HP, Tchistiakova L, Loganzo F, O'Donnell CJ,Sapra P.

ClinCancer Res. 2021 Jan 15;27(2):622-631.

SenescentT Cells as a Resistance Mechanism to Lung Cancer Immunotherapy.

衰老T细胞作为肺癌免疫治疗的耐药机制。

Salas-BenitoD, Eguren-Santamaria I, Sanmamed MF.

ClinCancer Res. 2021 Jan 15;27(2):374-376.

SelectedArticles from This Issue.

本期精选文章。

[Noauthors listed]

ClinCancer Res. 2021 Jan 15;27(2):369.

Clin Cancer Res[Jour] AND 27[volume] AND 3[issue]

临床癌症研究 27卷 3期

Siglec-15as an Emerging Target for Next-generation Cancer Immunotherapy.

Siglec-15作为新一代肿瘤免疫治疗的新靶点。

Sun J,Lu Q, Sanmanmed MF, Wang J.

ClinCancer Res. 2021 Feb 1;27(3):680-688.

NRF2Activation Promotes Aggressive Lung Cancer and Associates with Poor ClinicalOutcomes.

NRF2活化促进侵袭性肺癌的发生并与不良的临床结果相关。

SinghA, Daemen A, Nickles D, Jeon SM, Foreman O, Sudini K, Gnad F, Lajoie S, Gour N,Mitzner W, Chatterjee S, Choi EJ, Ravishankar B, Rappaport A, Patil N,McCleland M, Johnson L, Acquaah-Mensah G, Gabrielson E, Biswal S,Hatzivassiliou G.

ClinCancer Res. 2021 Feb 1;27(3):877-888.

IntratumoralImmunotherapy: From Trial Design to Clinical Practice.

肿瘤内免疫治疗：从试验设计到临床实践。

ChampiatS, Tselikas L, Farhane S, Raoult T, Texier M, Lanoy E, Massard C, Robert C,Ammari S, De Baère T, Marabelle A.

ClinCancer Res. 2021 Feb 1;27(3):665-679.

TheChanging Landscape of Therapeutic Cancer Vaccines-Novel Platforms andNeoantigen Identification.

治疗性癌症疫苗不断变化的前景新的平台和新抗原鉴定。

Jou J,Harrington KJ, Zocca MB, Ehrnrooth E, Cohen EEW.

ClinCancer Res. 2021 Feb 1;27(3):689-703.

OncolyticReovirus (pelareorep) Induces Autophagy in KRAS-mutated Colorectal Cancer.

溶瘤呼肠孤病毒（pelareorep）在KRAS突变的结直肠癌中诱导自噬。

JiffryJ, Thavornwatanayong T, Rao D, Fogel EJ, Saytoo D, Nahata R, Guzik H, ChaudharyI, Augustine T, Goel S, Maitra R.

ClinCancer Res. 2021 Feb 1;27(3):865-876.

Modificationof Extracellular Matrix Enhances Oncolytic Adenovirus Immunotherapy inGlioblastoma.

细胞外基质修饰增强胶质母细胞瘤溶瘤腺病毒免疫治疗。

KiyokawaJ, Kawamura Y, Ghouse SM, Acar S, Barçın E, Martínez-Quintanilla J, Martuza RL, Alemany R, Rabkin SD, Shah K, WakimotoH.

ClinCancer Res. 2021 Feb 1;27(3):889-902.

Regulationof CEACAM5 and Therapeutic Efficacy of an Anti-CEACAM5-SN38 Antibody-drugConjugate in Neuroendocrine Prostate Cancer.

CEACAM5的调节和抗CEACAM5-SN38抗体药物结合物治疗神经内分泌前列腺癌的疗效。

DeLuciaDC, Cardillo TM, Ang L, Labrecque MP, Zhang A, Hopkins JE, De Sarkar N, ColemanI, da Costa RMG, Corey E, True LD, Haffner MC, Schweizer MT, Morrissey C,Nelson PS, Lee JK.

ClinCancer Res. 2021 Feb 1;27(3):759-774.

PhaseII Study of Avelumab in Patients with Advanced Hepatocellular CarcinomaPreviously Treated with Sorafenib.

阿维鲁单抗在接受索拉非尼治疗的晚期肝癌患者中的II期研究。

LeeDW, Cho EJ, Lee JH, Yu SJ, Kim YJ, Yoon JH, Kim TY, Han SW, Oh DY, Im SA, KimTY, Lee Y, Kim H, Lee KH.

ClinCancer Res. 2021 Feb 1;27(3):713-718.

METExon 14-altered Lung Cancers and MET Inhibitor Resistance.

MET外显子14改变肺癌和MET抑制剂耐药性。

Guo R,Offin M, Brannon AR, Chang J, Chow A, Delasos L, Girshman J, Wilkins O,McCarthy CG, Makhnin A, Falcon C, Scott K, Tian Y, Cecchi F, Hembrough T, AlexD, Shen R, Benayed R, Li BT, Rudin CM, Kris MG, Arcila ME, Rekhtman N, Paik P,Zehir A, Drilon A.

ClinCancer Res. 2021 Feb 1;27(3):799-806.

ExploitingB-cell Receptor Stereotypy to Design Tailored Immunotherapy in ChronicLymphocytic Leukemia.

利用B细胞受体立体定向设计慢性淋巴细胞白血病的特异性免疫治疗。

RovidaA, Maccalli C, Scarfò L, Dellabona P, Stamatopoulos K, Ghia P.

ClinCancer Res. 2021 Feb 1;27(3):729-739.

IntegrativeAnalysis of miRNAs Identifies Clinically Relevant Epithelial and StromalSubtypes of Head and Neck Squamous Cell Carcinoma.

miRNAs的综合分析确定了头颈部鳞状细胞癌的临床相关上皮和间质亚型。

HoltJ, Walter V, Yin X, Marron D, Wilkerson MD, Choi HY, Zhao X, Jo H, Hayes DN, KoYH.

ClinCancer Res. 2021 Feb 1;27(3):831-842.

ClonalArchitecture of EGFR Mutation Predicts the Efficacy of EGFR-Tyrosine KinaseInhibitors in Advanced NSCLC: A Prospective Multicenter Study (NCT03059641).

EGFR突变克隆结构预测EGFR酪氨酸激酶抑制剂治疗晚期非小细胞肺癌的疗效：一项前瞻性多中心研究（NCT03059641）。

Ai X,Cui J, Zhang J, Chen R, Lin W, Xie C, Liu A, Zhang J, Yang W, Hu X, Hu X, ZhaoQ, Rao C, Zang YS, Ning R, Li P, Chang L, Yi X, Lu S.

ClinCancer Res. 2021 Feb 1;27(3):704-712.

ProteogenomicAnalysis of Salivary Adenoid Cystic Carcinomas Defines Molecular Subtypes andIdentifies Therapeutic Targets.

唾液腺样囊性癌的蛋白质基因组分析确定了分子亚型并确定了治疗靶点。

FerrarottoR, Mitani Y, McGrail DJ, Li K, Karpinets TV, Bell D, Frank SJ, Song X,Kupferman ME, Liu B, Lee JJ, Glisson BS, Zhang J, Aster JC, Lin SY, Futreal PA,Heymach JV, El-Naggar AK.

ClinCancer Res. 2021 Feb 1;27(3):852-864.

Effectsof HER Family-targeting Tyrosine Kinase Inhibitors on Antibody-dependentCell-mediated Cytotoxicity in HER2-expressing Breast Cancer.

她的家族靶向酪氨酸激酶抑制剂对表达HER2的乳腺癌中抗体依赖性细胞介导的细胞毒性的影响。

CollinsDM, Madden SF, Gaynor N, AlSultan D, Le Gal M, Eustace AJ, Gately KA, Hughes C,Davies AM, Mahgoub T, Ballot J, Toomey S, O'Connor DP, Gallagher WM, Holmes FA,Espina V, Liotta L, Hennessy BT, O'Byrne KJ, Hasmann M, Bossenmaier B,O'Donovan N, Crown J.

ClinCancer Res. 2021 Feb 1;27(3):807-818.

AntibodyPeptides as Cancer Vaccine-Turning Weapons to Targets.

抗体肽作为癌症疫苗将武器转化为靶点。

SeiffertM.

ClinCancer Res. 2021 Feb 1;27(3):659-661.

ANovel Neoplastic Fusion Transcript, RAD51AP1-DYRK4, Confers Sensitivity to theMEK Inhibitor Trametinib in Aggressive Breast Cancers.

一种新的肿瘤融合转录物RAD51AP1-DYRK4在侵袭性乳腺癌中对MEK抑制剂曲美替尼具有敏感性。

LiuCC, Veeraraghavan J, Tan Y, Kim JA, Wang X, Loo SK, Lee S, Hu Y, Wang XS.

ClinCancer Res. 2021 Feb 1;27(3):785-798.

ExploitingProtein Translation Dependence in Multiple Myeloma with Omacetaxine-BasedTherapy.

多发性骨髓瘤蛋白质翻译依赖性的研究。

WalkerZJ, Idler BM, Davis LN, Stevens BM, VanWyngarden MJ, Ohlstrom D, Bearrows SC,Hammes A, Smith CA, Jordan CT, Mark TM, Forsberg PA, Sherbenou DW.

ClinCancer Res. 2021 Feb 1;27(3):819-830.

ImmuneInfiltrate in the Primary Tumor Predicts Effect of Adjuvant Radiotherapy inBreast Cancer; Results from the Randomized SweBCG91RT Trial.

原发肿瘤中的免疫浸润预测乳腺癌辅助放疗的效果；来自随机SweBCG91RT试验的结果。

StenmarkTullberg A, Puttonen HAJ, Sjöström M, Holmberg E, Chang SL, Feng FY, Speers C,Pierce LJ, Lundstedt D, Killander F, Niméus E, Kovács A, Karlsson P.

ClinCancer Res. 2021 Feb 1;27(3):749-758.

AProspective Validation and Observer Performance Study of a Deep LearningAlgorithm for Pathologic Diagnosis of Gastric Tumors in Endoscopic Biopsies.

内镜活检胃肿瘤病理诊断深度学习算法的前瞻性验证和观察者性能研究。

ParkJ, Jang BG, Kim YW, Park H, Kim BH, Kim MJ, Ko H, Gwak JM, Lee EJ, Chung YR,Kim K, Myung JK, Park JH, Choi DY, Jung CW, Park BH, Jung KH, Kim DI.

ClinCancer Res. 2021 Feb 1;27(3):719-728.

ImprovedAssessment of Response Status in Patients with Pancreatic Cancer Treated withNeoadjuvant Therapy using Somatic Mutations and Liquid Biopsy Analysis.

利用体细胞突变和液体活检分析改进对胰腺癌新辅助治疗患者反应状态的评估。

Yin L,Pu N, Thompson E, Miao Y, Wolfgang C, Yu J.

ClinCancer Res. 2021 Feb 1;27(3):740-748.

HypofractionatedFLASH-RT as an Effective Treatment against Glioblastoma that ReducesNeurocognitive Side Effects in Mice.

低分割FLASH-RT是治疗胶质母细胞瘤的有效方法，可减少小鼠的神经认知副作用。

Montay-GruelP, Acharya MM, Gonçalves Jorge P, Petit B, Petridis IG, Fuchs P, Leavitt R, PeterssonK, Gondré M, Ollivier J, Moeckli R, Bochud F, Bailat C, Bourhis J, Germond JF,Limoli CL, Vozenin MC.

ClinCancer Res. 2021 Feb 1;27(3):775-784.

NewsFLASH-RT: To Treat GBM and Spare Cognition, Fraction Size and Total DoseMatter.

新闻快讯-放射治疗：治疗GBM和备用认知，分数大小和总剂量物质。

HuangCC, Mendonca MS.

ClinCancer Res. 2021 Feb 1;27(3):662-664.

Comparisonof Haploidentical Bone Marrow versus Matched Unrelated Donor Peripheral BloodStem Cell Transplantation with Posttransplant Cyclophosphamide in Patients withAcute Leukemia.

急性白血病患者单倍体相合骨髓与配对无关供者外周血干细胞移植联合环磷酰胺治疗的比较。

NaglerA, Labopin M, Dholaria B, Angelucci E, Afanasyev B, Cornelissen JJ, Sica S,Meijer E, Ciceri F, Van Gorkom G, Kröger N, Martin H, Pioltelli P, Risitano A,Canaani J, Savani BN, Sanz J, Mohty M.

ClinCancer Res. 2021 Feb 1;27(3):843-851.

SelectedArticles from This Issue.

本期精选文章。

[Noauthors listed]

ClinCancer Res. 2021 Feb 1;27(3):657.

Clin Cancer Res[Jour] AND 27[volume] AND 4[issue]

临床癌症研究 27卷 4期

Camrelizumabin Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma(RESCUE): A Nonrandomized, Open-label, Phase II Trial.

Camrelizumab联合阿替尼治疗晚期肝细胞癌（RESCUE）：一项非随机、开放标签、II期试验。

Xu J,Shen J, Gu S, Zhang Y, Wu L, Wu J, Shao G, Zhang Y, Xu L, Yin T, Liu J, Ren Z,Xiong J, Mao X, Zhang L, Yang J, Li L, Chen X, Wang Z, Gu K, Chen X, Pan Z, MaK, Zhou X, Yu Z, Li E, Yin G, Zhang X, Wang S, Wang Q.

ClinCancer Res. 2021 Feb 15;27(4):1003-1011.

ST6GAL1Is a Novel Serum Biomarker for Lenvatinib-Susceptible FGF19-Driven HepatocellularCarcinoma.

ST6GAL1是一种新的Lenvatinib敏感的FGF19驱动的肝细胞癌血清生物标志物。

MyojinY, Kodama T, Maesaka K, Motooka D, Sato Y, Tanaka S, Abe Y, Ohkawa K, Mita E,Hayashi Y, Hikita H, Sakamori R, Tatsumi T, Taguchi A, Eguchi H, Takehara T.

ClinCancer Res. 2021 Feb 15;27(4):1150-1161.

RandomizedPhase II and Biomarker Study of Pembrolizumab plus Bevacizumab versusPembrolizumab Alone for Patients with Recurrent Glioblastoma.

Pembrolizumab联合贝伐单抗与Pembrolizumab单独治疗复发性胶质母细胞瘤的随机II期和生物标志物研究。

NayakL, Molinaro AM, Peters K, Clarke JL, Jordan JT, de Groot J, Nghiemphu L, KaleyT, Colman H, McCluskey C, Gaffey S, Smith TR, Cote DJ, Severgnini M, YearleyJH, Zhao Q, Blumenschein WM, Duda DG, Muzikansky A, Jain RK, Wen PY, ReardonDA.

ClinCancer Res. 2021 Feb 15;27(4):1048-1057.

WORLDCANCER RESEARCH DAY: A Call to Action for a Coordinated International ResearchEffort to Prevent, Diagnose, and Treat Cancer.

世界癌症研究日：呼吁采取行动，协调国际研究工作，以预防、诊断和治疗癌症。

PuyolM, Seoane J, Aguilar E, Vozza LB, Orbe I, Crawford KH, Fernández A, Bray F, JohnsonSE, Gopal S.

ClinCancer Res. 2021 Feb 15;27(4):963-966.

Discriminationof Breast Cancer from Healthy Breast Tissue Using a Three-componentDiffusion-weighted MRI Model.

利用三分量扩散加权磁共振模型鉴别乳腺癌和健康乳腺组织。

AndreassenMMS, Rodríguez-Soto AE, Conlin CC, Vidić I, Seibert TM, Wallace AM, Zare S,Kuperman J, Abudu B, Ahn GS, Hahn M, Jerome NP, Østlie A, Bathen TF, Ojeda-Fournier H, GoaPE, Rakow-Penner R, Dale AM.

ClinCancer Res. 2021 Feb 15;27(4):1094-1104.

Optimizingthe Use of Telemedicine in Oncology Care: Postpandemic Opportunities.

优化远程医疗在肿瘤治疗中的应用：后癌症治疗的机会。

KnudsenKE, Willman C, Winn R.

ClinCancer Res. 2021 Feb 15;27(4):933-936.

GenomicCharacterization of de novo Metastatic Breast Cancer.

新发转移性乳腺癌的基因组特征。

Garrido-CastroAC, Spurr LF, Hughes ME, Li YY, Cherniack AD, Kumari P, Lloyd MR, Bychkovsky B,Barroso-Sousa R, Di Lascio S, Jain E, Files J, Mohammed-Abreu A, Krevalin M,MacKichan C, Barry WT, Guo H, Xia D, Cerami E, Rollins BJ, MacConaill LE, LindemanNI, Krop IE, Johnson BE, Wagle N, Winer EP, Dillon DA, Lin NU.

ClinCancer Res. 2021 Feb 15;27(4):1105-1118.

TheChallenge of Combining Chemo- and Radiotherapy with Checkpoint KinaseInhibitors.

化疗和放疗联合应用检查点激酶抑制剂的挑战。

vanBijsterveldt L, Durley SC, Maughan TS, Humphrey TC.

ClinCancer Res. 2021 Feb 15;27(4):937-962.

TherapeuticPotential of NTRK3 Inhibition in Desmoplastic Small Round Cell Tumor.

抑制NTRK3对促结缔组织增生性小圆细胞瘤的治疗潜力。

OguraK, Somwar R, Hmeljak J, Magnan H, Benayed R, Momeni Boroujeni A, Bowman AS,Mattar MS, Khodos I, de Stanchina E, Jungbluth A, Asher M, Odintsov I, HartonoAB, LaQuaglia MP, Slotkin E, Pratilas CA, Lee SB, Spraggon L, Ladanyi M.

ClinCancer Res. 2021 Feb 15;27(4):1184-1194.

ARandomized Phase IIb Study of Low-dose Tamoxifen in Chest-irradiated CancerSurvivors at Risk for Breast Cancer.

低剂量他莫昔芬在胸部照射有乳腺癌风险的癌症幸存者中的随机IIb期研究。

BhatiaS, Palomares MR, Hageman L, Chen Y, Landier W, Smith K, Umphrey H, Reich CA,Zamora KW, Armenian SH, Bevers TB, Blaes A, Henderson T, Hodgson D, Hudson MM,Korde LA, Melin SA, Merajver SD, Overholser L, Pruthi S, Wong FL, Garber JE.

ClinCancer Res. 2021 Feb 15;27(4):967-974.

Composition,Spatial Characteristics, and Prognostic Significance of Myeloid CellInfiltration in Pancreatic Cancer.

胰腺癌髓细胞浸润的组成、空间特征和预后意义。

VäyrynenSA, Zhang J, Yuan C, Väyrynen JP, Dias Costa A, Williams H, Morales-Oyarvide V,Lau MC, Rubinson DA, Dunne RF, Kozak MM, Wang W, Agostini-Vulaj D, Drage MG,Brais L, Reilly E, Rahma O, Clancy T, Wang J, Linehan DC, Aguirre AJ, Fuchs CS,Coussens LM, Chang DT, Koong AC, Hezel AF, Ogino S, Nowak JA, Wolpin BM.

ClinCancer Res. 2021 Feb 15;27(4):1069-1081.

TranscriptionalSubtypes Resolve Tumor Heterogeneity and Identify Vulnerabilities to MEKInhibition in Lung Adenocarcinoma.

转录亚型可解决肺腺癌中肿瘤异质性并识别MEK抑制的脆弱性。

DaemenA, Cooper JE, Myrta S, Wongchenko MJ, Lin E, Long JE, Foreman O, Modrusan Z,Tremayne JR, de la Cruz CC, Merchant M, Martin SE, Yan Y, Junttila MR.

ClinCancer Res. 2021 Feb 15;27(4):1162-1173.

SomaticEpigenetic Silencing of RIPK3 Inactivates Necroptosis and Contributes toChemoresistance in Malignant Mesothelioma.

RIPK3的体细胞表观遗传沉默使恶性间皮瘤坏死下垂失活并导致化疗耐药。

Tan Y,Sementino E, Cheung M, Peri S, Menges CW, Kukuyan AM, Zhang T, Khazak V, FoxLA, Ross EA, Ramanathan S, Jhanwar SC, Flores RM, Balachandran S, Testa JR.

ClinCancer Res. 2021 Feb 15;27(4):1200-1213.

Entinostatplus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated withAnti-PD-(L)1 Therapy.

恩替诺司他联合Pembrolizumab治疗转移性非小细胞肺癌患者的疗效。

HellmannMD, Jänne PA, Opyrchal M, Hafez N, Raez LE, Gabrilovich DI, Wang F, Trepel JB,Lee MJ, Yuno A, Lee S, Brouwer S, Sankoh S, Wang L, Tamang D, Schmidt EV,Meyers ML, Ramalingam SS, Shum E, Ordentlich P.

ClinCancer Res. 2021 Feb 15;27(4):1019-1028.

FDAApproval Summary: Enfortumab Vedotin for Locally Advanced or MetastaticUrothelial Carcinoma.

FDA批准摘要：Enfortumab Vedotin治疗局部晚期或转移性尿路上皮癌。

ChangE, Weinstock C, Zhang L, Charlab R, Dorff SE, Gong Y, Hsu V, Li F, Ricks TK,Song P, Tang S, Waldron PE, Yu J, Zahalka E, Goldberg KB, Pazdur R, Theoret MR,Ibrahim A, Beaver JA.

ClinCancer Res. 2021 Feb 15;27(4):922-927.

MulticenterPhase I/II Study of Nivolumab Combined with Paclitaxel Plus Ramucirumab asSecond-line Treatment in Patients with Advanced Gastric Cancer.

Nivolumab联合紫杉醇和Ramucirumab二线治疗晚期胃癌的多中心I/II期研究。

NakajimaTE, Kadowaki S, Minashi K, Nishina T, Yamanaka T, Hayashi Y, Izawa N, Muro K,Hironaka S, Kajiwara T, Kawakami Y.

ClinCancer Res. 2021 Feb 15;27(4):1029-1036.

Impactof Body Mass Index on Presence of ctDNA and Disease Recurrence afterNeoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Analysis fromBRE12-158.

体重指数对三阴性乳腺癌新辅助化疗后ctDNA和疾病复发的影响：来自BRE12-158的分析。

BallingerTJ, Jiang G, Kassem N, Radovich M, Schneider BP.

ClinCancer Res. 2021 Feb 15;27(4):1195-1199.

RandomizedPhase II Trial of Anthracycline-free and Anthracycline-containing NeoadjuvantCarboplatin Chemotherapy Regimens in Stage I-III Triple-negative Breast Cancer(NeoSTOP).

无蒽环类药物和含蒽环类药物的卡铂新辅助化疗方案治疗I-III期三阴性乳腺癌（NeoSTOP）的随机II期试验。

SharmaP, Kimler BF, O'Dea A, Nye L, Wang YY, Yoder R, Staley JM, Prochaska L, WagnerJ, Amin AL, Larson K, Balanoff C, Elia M, Crane G, Madhusudhana S, Hoffmann M,Sheehan M, Rodriguez R, Finke K, Shah R, Satelli D, Shrestha A, Beck L, McKittrickR, Pluenneke R, Raja V, Beeki V, Corum L, Heldstab J, LaFaver S, Prager M,Phadnis M, Mudaranthakam DP, Jensen RA, Godwin AK, Salgado R, Mehta K, Khan Q.

ClinCancer Res. 2021 Feb 15;27(4):975-982.

ClinicalValidation of a Machine-learning-derived Signature Predictive of Outcomes fromFirst-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer.

机器学习衍生特征预测晚期结直肠癌一线奥沙利铂化疗结果的临床验证。

AbrahamJP, Magee D, Cremolini C, Antoniotti C, Halbert DD, Xiu J, Stafford P, BerryDA, Oberley MJ, Shields AF, Marshall JL, Salem ME, Falcone A, Grothey A, HallMJ, Venook AP, Lenz HJ, Helmstetter A, Korn WM, Spetzler DB.

ClinCancer Res. 2021 Feb 15;27(4):1174-1183.

APhase I Trial of Talimogene Laherparepvec in Combination with NeoadjuvantChemotherapy for the Treatment of Nonmetastatic Triple-Negative Breast Cancer.

泰利莫金联合新辅助化疗治疗非转移性三阴性乳腺癌的Ⅰ期临床研究。

SolimanH, Hogue D, Han H, Mooney B, Costa R, Lee MC, Niell B, Williams A, Chau A,Falcon S, Khakpour N, Weinfurtner RJ, Hoover S, Kiluk J, Rosa M, Khong H,Czerniecki B.

ClinCancer Res. 2021 Feb 15;27(4):1012-1018.

CombiningNivolumab and Ipilimumab with Infliximab or Certolizumab in Patients withAdvanced Melanoma: First Results of a Phase Ib Clinical Trial.

Nivolumab和Ipilimumab联合Infliximab或Certolizumab治疗晚期黑色素瘤：Ib期临床试验的首次结果。

MontfortA, Filleron T, Virazels M, Dufau C, Milhès J, Pagès C, Olivier P, Ayyoub M,Mounier M, Lusque A, Brayer S, Delord JP, Andrieu-Abadie N, Levade T, ColaciosC, Ségui B, Meyer N.

ClinCancer Res. 2021 Feb 15;27(4):1037-1047.

Cobomarsen,an Oligonucleotide Inhibitor of miR-155, Slows DLBCL Tumor Cell Growth In Vitroand In Vivo.

Cobomarsen是一种miR-155的寡核苷酸抑制剂，在体内外减缓DLBCL肿瘤细胞的生长。

AnastasiadouE, Seto AG, Beatty X, Hermreck M, Gilles ME, Stroopinsky D, Pinter-Brown LC,Pestano L, Marchese C, Avigan D, Trivedi P, Escolar DM, Jackson AL, Slack FJ.

ClinCancer Res. 2021 Feb 15;27(4):1139-1149.

PredictingCAR-T cell Immunotherapy Success through ImmunoPET.

通过免疫pet预测CAR-T细胞免疫治疗的成功。

VolpeA, Nagle VL, Lewis JS, Ponomarev V.

ClinCancer Res. 2021 Feb 15;27(4):911-912.

Osimertinibplus Ramucirumab: The Best of Both Worlds?

奥西莫替尼加拉莫昔单抗：两全其美？

GaronEB.

ClinCancer Res. 2021 Feb 15;27(4):905-907.

ClinicalEfficacy and Molecular Response Correlates of the WEE1 Inhibitor AdavosertibCombined with Cisplatin in Patients with Metastatic Triple-Negative BreastCancer.

WEE1抑制剂Adavosertib联合顺铂治疗转移性三阴性乳腺癌的临床疗效及分子反应相关性研究。

KeenanTE, Li T, Vallius T, Guerriero JL, Tayob N, Kochupurakkal B, Davis J,Pastorello R, Tahara RK, Anderson L, Conway J, He MX, Shannon E, Godin RE,Sorger PK, D'Andrea A, Overmoyer B, Winer EP, Mittendorf EA, Van Allen EM,Shapiro GI, Tolaney SM.

ClinCancer Res. 2021 Feb 15;27(4):983-991.

TranscriptionStrikes Back: Clinical Utility of Lung Adenocarcinoma Subtypes.

转录反击：肺腺癌亚型的临床应用。

SkoulidisF.

ClinCancer Res. 2021 Feb 15;27(4):913-915.

EarlyAdaptation of Colorectal Cancer Cells to the Peritoneal Cavity Is Associatedwith Activation of "Stemness" Programs and Local Inflammation.

结直肠癌细胞对腹膜腔的早期适应与“干细胞”程序的激活和局部炎症有关。

BarriusoJ, Nagaraju RT, Belgamwar S, Chakrabarty B, Burghel GJ, Schlecht H, Foster L,Kilgour E, Wallace AJ, Braun M, Dive C, Evans DG, Bristow RG, Saunders MP,O'Dwyer ST, Aziz O.

ClinCancer Res. 2021 Feb 15;27(4):1119-1130.

PhaseI Study of the Efficacy and Safety of Ramucirumab in Combination withOsimertinib in Advanced T790M-positive EGFR-mutant Non-small Cell Lung Cancer.

Ramucirumab联合Osimertinib治疗晚期T790M阳性EGFR突变非小细胞肺癌的疗效和安全性的I期研究。

Yu HA,Paz-Ares LG, Yang JC, Lee KH, Garrido P, Park K, Kim JH, Lee DH, Mao H,Wijayawardana SR, Gao L, Hozak RR, Chao BH, Planchard D.

ClinCancer Res. 2021 Feb 15;27(4):992-1002.

MolecularImaging of Chimeric Antigen Receptor T Cells by ICOS-ImmunoPET.

嵌合抗原受体T细胞的ICOS免疫pet分子显像。

SimonettaF, Alam IS, Lohmeyer JK, Sahaf B, Good Z, Chen W, Xiao Z, Hirai T, Scheller L,Engels P, Vermesh O, Robinson E, Haywood T, Sathirachinda A, Baker J,Malipatlolla MB, Schultz LM, Spiegel JY, Lee JT, Miklos DB, Mackall CL, GambhirSS, Negrin RS.

ClinCancer Res. 2021 Feb 15;27(4):1058-1068.

FDAApproval Summary: Entrectinib for the Treatment of NTRK gene Fusion SolidTumors.

FDA批准摘要：恩曲替尼用于治疗NTRK基因融合实体瘤。

MarcusL, Donoghue M, Aungst S, Myers CE, Helms WS, Shen G, Zhao H, Stephens O, KeeganP, Pazdur R.

ClinCancer Res. 2021 Feb 15;27(4):928-932.

DeepLearning Predicts HPV Association in Oropharyngeal Squamous Cell Carcinomas andIdentifies Patients with a Favorable Prognosis Using Regular H&E Stains.

深度学习预测口咽鳞状细胞癌中的HPV相关性，并使用常规H&E染色确定预后良好的患者。

KleinS, Quaas A, Quantius J, Löser H, Meinel J, Peifer M, Wagner S, Gattenlöhner S,Wittekindt C, von Knebel Doeberitz M, Prigge ES, Langer C, Noh KW, Maltseva M,Reinhardt HC, Büttner R, Klussmann JP, Wuerdemann N.

ClinCancer Res. 2021 Feb 15;27(4):1131-1138.

FDAOncology Center of Excellence Project Renewal: Engaging the Oncology Communityto Update Product Labeling for Older Oncology Drugs.

FDA肿瘤学卓越中心项目更新：让肿瘤学界为旧的肿瘤学药物更新产品标签。

KluetzPG, Keegan P, Demetri GD, Thornton K, Sul J, Kim J, Katzen H, Burke LB, HarveyRD, Alebachew E, Agrawal S, Nair A, Donoghue M, Pierce WF, Shord SS, Gao JJ,Pazdur R.

ClinCancer Res. 2021 Feb 15;27(4):916-921.

CombinedPD-1/VEGFR Blockade: A New Era of Treatment for Hepatocellular Cancer.

PD-1/VEGFR联合阻断：肝细胞癌治疗的新纪元。

PinatoDJ, Fessas P, Cortellini A, Rimassa L.

ClinCancer Res. 2021 Feb 15;27(4):908-910.

Definingthe Comprehensive Genomic Landscapes of Pancreatic Ductal Adenocarcinoma UsingReal-World Endoscopic Aspiration Samples.

使用真实世界的内镜抽吸样本确定胰腺导管腺癌的全面基因组图谱。

SemaanA, Bernard V, Lee JJ, Wong JW, Huang J, Swartzlander DB, Stephens BM, MonbergME, Weston BR, Bhutani MS, Chang K, Scheet PA, Maitra A, Jakubek YA, GuerreroPA.

ClinCancer Res. 2021 Feb 15;27(4):1082-1093.

SelectedArticles from This Issue.

本期精选文章。

[Noauthors listed]

ClinCancer Res. 2021 Feb 15;27(4):903.

Clin Cancer Res[Jour] AND 27[volume] AND 5[issue]

临床癌症研究 27卷 5期

B7-H3:An Attractive Target for Antibody-based Immunotherapy.

B7-H3：抗体免疫治疗的一个有吸引力的靶点。

KontosF, Michelakos T, Kurokawa T, Sadagopan A, Schwab JH, Ferrone CR, Ferrone S.

ClinCancer Res. 2021 Mar 1;27(5):1227-1235.

MolecularImaging of Prostate Cancer Targeting CD46 Using ImmunoPET.

前列腺癌靶向CD46分子显像的免疫pet研究。

WangS, Li J, Hua J, Su Y, Beckford-Vera DR, Zhao W, Jayaraman M, Huynh TL, Zhao N,Wang YH, Huang Y, Qin F, Shen S, Gioeli D, Dreicer R, Sriram R, Egusa EA, ChouJ, Feng FY, Aggarwal R, Evans MJ, Seo Y, Liu B, Flavell RR, He J.

ClinCancer Res. 2021 Mar 1;27(5):1305-1315.

YAP/TAZTranscriptional Coactivators Create Therapeutic Vulnerability to Verteporfin inEGFR-mutant Glioblastoma.

YAP/TAZ转录辅激活子在EGFR突变胶质母细胞瘤中对Verteporfin产生治疗脆弱性。

VigneswaranK, Boyd NH, Oh SY, Lallani S, Boucher A, Neill SG, Olson JJ, Read RD.

ClinCancer Res. 2021 Mar 1;27(5):1553-1569.

Efficacyand Biomarker Analysis of Camrelizumab in Combination with Apatinib in Patientswith Advanced Nonsquamous NSCLC Previously Treated with Chemotherapy.

卡美瑞珠单抗联合阿替尼治疗晚期非鳞状细胞癌的疗效及生物标志物分析。

ZhouC, Wang Y, Zhao J, Chen G, Liu Z, Gu K, Huang M, He J, Chen J, Ma Z, Feng J,Shi J, Yu X, Cheng Y, Yao Y, Chen Y, Guo R, Lin X, Wang Z, Gao G, Wang Q, Li W,Yang X, Wu L, Zhang J, Ren S.

ClinCancer Res. 2021 Mar 1;27(5):1296-1304.

EarlyDiscontinuation of Endocrine Therapy and Recurrence of Breast Cancer amongPremenopausal Women.

绝经前妇女早期停止内分泌治疗与乳腺癌复发。

CollinLJ, Cronin-Fenton DP, Ahern TP, Goodman M, McCullough LE, Waller LA, KjærsgaardA, Damkier P, Christiansen PM, Ejlertsen B, Jensen MB, Sørensen HT, Lash TL.

ClinCancer Res. 2021 Mar 1;27(5):1421-1428.

Expressionof T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as PredictiveBiomarkers for Response to Nivolumab in Metastatic Clear Cell Renal CellCarcinoma.

T细胞衰竭分子和人内源性逆转录病毒的表达作为转移性透明细胞肾癌对Nivolumab反应的预测性生物标志物。

FicialM, Jegede OA, Sant'Angelo M, Hou Y, Flaifel A, Pignon JC, Braun DA, Wind-RotoloM, Sticco-Ivins MA, Catalano PJ, Freeman GJ, Sharpe AH, Hodi FS, Motzer RJ, WuCJ, Atkins MB, McDermott DF, Shukla SA, Choueiri TK, Signoretti S.

ClinCancer Res. 2021 Mar 1;27(5):1371-1380.

Characterizationand Clinical Outcomes of DNA Mismatch Repair-deficient Small BowelAdenocarcinoma.

DNA错配修复缺陷型小肠腺癌的特征和临床结果。

LathamA, Shia J, Patel Z, Reidy-Lagunes DL, Segal NH, Yaeger R, Ganesh K, Connell L,Kemeny NE, Kelsen DP, Hechtman JF, Nash GM, Paty PB, Zehir A, Tkachuk KA,Sheikh R, Markowitz AJ, Mandelker D, Offit K, Berger MF, Cercek A,Garcia-Aguilar J, Saltz LB, Weiser MR, Stadler ZK.

ClinCancer Res. 2021 Mar 1;27(5):1429-1437.

GutMicrobiome Components Predict Response to Neoadjuvant Chemoradiotherapy inPatients with Locally Advanced Rectal Cancer: A Prospective, LongitudinalStudy.

肠道微生物组分预测局部晚期直肠癌患者对新辅助放化疗的反应：一项前瞻性纵向研究。

Yi Y,Shen L, Shi W, Xia F, Zhang H, Wang Y, Zhang J, Wang Y, Sun X, Zhang Z, Zou W,Yang W, Zhang L, Zhu J, Goel A, Ma Y, Zhang Z.

ClinCancer Res. 2021 Mar 1;27(5):1329-1340.

AMG757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows HighPotency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer.

AMG757是一种半衰期延长的DLL3靶向双特异性T细胞接合器，在小细胞肺癌的临床前模型中表现出很高的效力和敏感性。

GiffinMJ, Cooke K, Lobenhofer EK, Estrada J, Zhan J, Deegen P, Thomas M, Murawsky CM,Werner J, Liu S, Lee F, Homann O, Friedrich M, Pearson JT, Raum T, Yang Y,Caenepeel S, Stevens J, Beltran PJ, Canon J, Coxon A, Bailis JM, Hughes PE.

ClinCancer Res. 2021 Mar 1;27(5):1526-1537.

TarloxotinibIs a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range ofHER-Family Oncogenes.

他洛昔尼是一种缺氧激活的泛HER激酶抑制剂，对广泛的家族癌基因具有活性。

Estrada-BernalA, Le AT, Doak AE, Tirunagaru VG, Silva S, Bull MR, Smaill JB, Patterson AV,Kim C, Liu SV, Doebele RC.

ClinCancer Res. 2021 Mar 1;27(5):1463-1475.

Eradicationof T-ALL Cells by CD7-targeted Universal CAR-T Cells and Initial Test ofRuxolitinib-based CRS Management.

用CD7靶向的通用型CAR-T细胞根除T-ALL细胞和基于鲁索利替尼的CRS治疗的初步试验。

Li S,Wang X, Yuan Z, Liu L, Luo L, Li Y, Wu K, Liu J, Yang C, Li Z, Wang D, Shen L,Ye X, He J, Han C, Wang Y, Zhang D, Dong Y, Fang L, Chen Y, Sersch M, Cao WW,Wang S.

ClinCancer Res. 2021 Mar 1;27(5):1242-1246.

APerformance Comparison of Commonly Used Assays to Detect RET Fusions.

检测RET融合的常用分析方法的性能比较。

YangSR, Aypar U, Rosen EY, Mata DA, Benayed R, Mullaney K, Jayakumaran G, Zhang Y,Frosina D, Drilon A, Ladanyi M, Jungbluth AA, Rekhtman N, Hechtman JF.

ClinCancer Res. 2021 Mar 1;27(5):1316-1328.

177Lu-DOTA-EB-TATE,a Radiolabeled Analogue of Somatostatin Receptor Type 2, for the Imaging andTreatment of Thyroid Cancer.

177LuDOTA-EB-TATE，生长抑素受体2型的放射性标记类似物，用于甲状腺癌的显像和治疗。

ThakurS, Daley B, Millo C, Cochran C, Jacobson O, Lu H, Wang Z, Kiesewetter D, ChenX, Vasko V, Klubo-Gwiezdzinska J.

ClinCancer Res. 2021 Mar 1;27(5):1399-1409.

CirculatingTumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to CombinationImmunotherapy in Patients with Metastatic Genitourinary Cancer.

循环肿瘤细胞亚型和T细胞群作为联合免疫治疗转移性泌尿生殖道癌患者预后的生物标志物。

ChalfinHJ, Pramparo T, Mortazavi A, Niglio SA, Schonhoft JD, Jendrisak A, Chu YL,Richardson R, Krupa R, Anderson AKL, Wang Y, Dittamore R, Pal SK, Lara PN,Stein MN, Quinn DI, Steinberg SM, Cordes LM, Ley L, Mallek M, Sierra Ortiz O,Costello R, Cadena J, Diaz C, Gulley JL, Dahut WL, Streicher H, Wright JJ,Trepel JB, Bottaro DP, Apolo AB.

ClinCancer Res. 2021 Mar 1;27(5):1391-1398.

Ipilimumaband Radiation in Patients with High-risk Resected or Regionally AdvancedMelanoma.

高危切除或局部晚期黑色素瘤患者的伊普利单抗和放疗。

SalamaAKS, Palta M, Rushing CN, Selim MA, Linney KN, Czito BG, Yoo DS, Hanks BA,Beasley GM, Mosca PJ, Dumbauld C, Steadman KN, Yi JS, Weinhold KJ, Tyler DS,Lee WT, Brizel DM.

ClinCancer Res. 2021 Mar 1;27(5):1287-1295.

CombinedInhibition of Gαq and MEK Enhances Therapeutic Efficacy in Uveal Melanoma.

联合抑制Gαq和MEK可提高葡萄膜黑色素瘤的疗效。

HitchmanTD, Bayshtok G, Ceraudo E, Moore AR, Lee C, Jia R, Wang N, Pachai MR,Shoushtari AN, Francis JH, Guan Y, Chen J, Chang MT, Taylor BS, Sakmar TP,Huber T, Chi P, Chen Y.

ClinCancer Res. 2021 Mar 1;27(5):1476-1490.

TheGenetic Evolution of Treatment-Resistant Cutaneous, Acral, and Uveal Melanomas.

难治性皮肤、肢端和葡萄膜黑色素瘤的遗传进化。

Makohon-MooreAP, Lipson EJ, Hooper JE, Zucker A, Hong J, Bielski CM, Hayashi A, Tokheim C,Baez P, Kappagantula R, Kohutek Z, Makarov V, Riaz N, Postow MA, Chapman PB,Karchin R, Socci ND, Solit DB, Chan TA, Taylor BS, Topalian SL, Iacobuzio-DonahueCA.

ClinCancer Res. 2021 Mar 1;27(5):1516-1525.

FGFRInhibition Overcomes Resistance to EGFR-targeted Therapy in Epithelial-likeCutaneous Carcinoma.

FGFR抑制克服上皮样皮肤癌对EGFR靶向治疗的耐药性。

Bernat-PegueraA, Navarro-Ventura J, Lorenzo-Sanz L, da Silva-Diz V, Bosio M, Palomero L,Penin RM, Pérez Sidelnikova D, Bermejo JO, Taberna M, Vilariño N, Piulats JM,Mesia R, Viñals JM, González-Suárez E, Capella-Gutierrez S, Villanueva A,Viñals F, Muñoz P.

ClinCancer Res. 2021 Mar 1;27(5):1491-1504.

PhaseI Study of Everolimus, Letrozole, and Trastuzumab in Patients with HormoneReceptor-positive Metastatic Breast Cancer or Other Solid Tumors.

依维莫司、来曲唑和曲妥珠单抗治疗激素受体阳性转移性乳腺癌或其他实体瘤患者的I期研究。

BallhausenA, Wheler JJ, Karp DD, Piha-Paul SA, Fu S, Pant S, Tsimberidou AM, Hong DS,Subbiah V, Holley VR, Huang HJ, Brewster AM, Koenig KB, Ibrahim NK,Meric-Bernstam F, Janku F.

ClinCancer Res. 2021 Mar 1;27(5):1247-1255.

High-doseper Fraction Radiotherapy Induces Both Antitumor Immunity and ImmunosuppressiveResponses in Prostate Tumors.

高剂量单次放射治疗可诱导前列腺肿瘤的抗肿瘤免疫和免疫抑制反应。

Lin L,Kane N, Kobayashi N, Kono EA, Yamashiro JM, Nickols NG, Reiter RE.

ClinCancer Res. 2021 Mar 1;27(5):1505-1515.

PhaseI and Pharmacologic Study of Olaparib in Combination with High-doseRadiotherapy with and without Concurrent Cisplatin for Non-Small Cell LungCancer.

奥拉帕利联合大剂量放疗加顺铂和不加顺铂治疗非小细胞肺癌的Ⅰ期及药理学研究。

deHaan R, van den Heuvel MM, van Diessen J, Peulen HMU, van Werkhoven E, deLangen AJ, Lalezari F, Pluim D, Verwijs-Janssen M, Vens C, Schellens JHM,Steeghs N, Verheij M, van Triest B.

ClinCancer Res. 2021 Mar 1;27(5):1256-1266.

TheUse of Serial Circulating Tumor DNA to Detect Resistance Alterations inProgressive Metastatic Breast Cancer.

应用循环肿瘤DNA检测进展性转移性乳腺癌的耐药改变。

JacobS, Davis AA, Gerratana L, Velimirovic M, Shah AN, Wehbe F, Katam N, Zhang Q,Flaum L, Siziopikou KP, Platanias LC, Gradishar WJ, Behdad A, Bardia A,Cristofanilli M.

ClinCancer Res. 2021 Mar 1;27(5):1361-1370.

ProteasomeInhibition Overcomes ALK-TKI Resistance in ALK-Rearranged/TP53-Mutant NSCLC viaNoxa Expression.

蛋白酶体抑制通过Noxa表达克服ALK重排/TP53突变NSCLC中的ALK-TKI抗性。

TanimotoA, Matsumoto S, Takeuchi S, Arai S, Fukuda K, Nishiyama A, Yoh K, Ikeda T,Furuya N, Nishino K, Ohe Y, Goto K, Yano S.

ClinCancer Res. 2021 Mar 1;27(5):1410-1420.

CamGFRv2: A New Model for Estimating the Glomerular Filtration Rate from Standardizedor Non-standardized Creatinine in Patients with Cancer.

camgfrv2：一种从标准化或非标准化肌酐评估癌症患者肾小球滤过率的新模型。

WilliamsEH, Flint TR, Connell CM, Giglio D, Lee H, Ha T, Gablenz E, Bird NJ, WeaverJMJ, Potts H, Whitley CT, Bookman MA, Lynch AG, Meyer HV, Tavaré S, Janowitz T.

ClinCancer Res. 2021 Mar 1;27(5):1381-1390.

TargetedTherapy of TERT-Rearranged Neuroblastoma with BET Bromodomain Inhibitor andProteasome Inhibitor Combination Therapy.

BET-溴吗啉抑制剂和蛋白酶体抑制剂联合治疗TERT重排神经母细胞瘤。

ChenJ, Nelson C, Wong M, Tee AE, Liu PY, La T, Fletcher JI, Kamili A, Mayoh C,Bartenhagen C, Trahair TN, Xu N, Jayatilleke N, Wong M, Peng H, Atmadibrata B,Cheung BB, Lan Q, Bryan TM, Mestdagh P, Vandesompele J, Combaret V, Boeva V,Wang JY, Janoueix-Lerosey I, Cowley MJ, MacKenzie KL, Dolnikov A, Li J, PollyP, Marshall GM, Reddel RR, Norris MD, Haber M, Fischer M, Zhang XD, Pickett HA,Liu T.

ClinCancer Res. 2021 Mar 1;27(5):1438-1451.

GenomeMethylation Accurately Predicts Neuroendocrine Tumor Origin: An Online Tool.

基因组甲基化准确预测神经内分泌肿瘤起源：一个在线工具。

HackengWM, Dreijerink KMA, de Leng WWJ, Morsink FHM, Valk GD, Vriens MR, OfferhausGJA, Geisenberger C, Brosens LAA.

ClinCancer Res. 2021 Mar 1;27(5):1341-1350.

FinalResults of the Prospective Biomarker Trial PETra: [11C]-MET-Accumulation inPostoperative PET/MRI Predicts Outcome after Radiochemotherapy in Glioblastoma.

前瞻性生物标志物试验PETra:[11C]-MET在胶质母细胞瘤术后PET/MRI中的累积预测了放化疗后的预后。

SeidlitzA, Beuthien-Baumann B, Löck S, Jentsch C, Platzek I, Zöphel K, Linge A,Kotzerke J, Petr J, van den Hoff J, Steinbach J, Krex D, Schmitz-Schackert G,Falk M, Baumann M, Krause M.

ClinCancer Res. 2021 Mar 1;27(5):1351-1360.

FDAApproval Summary: Tucatinib for the Treatment of Patients with Advanced orMetastatic HER2-positive Breast Cancer.

FDA批准摘要：图卡替尼用于治疗晚期或转移性HER2阳性乳腺癌患者。

ShahM, Wedam S, Cheng J, Fiero MH, Xia H, Li F, Fan J, Zhang X, Yu J, Song P, ChenW, Ricks TK, Chen XH, Goldberg KB, Gong Y, Pierce WF, Tang S, Theoret MR,Pazdur R, Amiri-Kordestani L, Beaver JA.

ClinCancer Res. 2021 Mar 1;27(5):1220-1226.

PreclinicalCharacterization of HPN536, a Trispecific, T-Cell-Activating Protein Constructfor the Treatment of Mesothelin-Expressing Solid Tumors.

用于治疗间皮素表达实体瘤的三特异性T细胞活化蛋白结构HPN536的临床前特征。

MolloyME, Austin RJ, Lemon BD, Aaron WH, Ganti V, Jones A, Jones SD, Strobel KL,Patnaik P, Sexton K, Tatalick L, Yu TZ, Baeuerle PA, Law CL, Wesche H.

ClinCancer Res. 2021 Mar 1;27(5):1452-1462.

TumorMutational Burden as a Predictor of Immunotherapy Response: Is More AlwaysBetter?

肿瘤突变负荷作为免疫治疗反应的预测因子：越多越好？

StricklerJH, Hanks BA, Khasraw M.

ClinCancer Res. 2021 Mar 1;27(5):1236-1241.

Safetyand Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combinedwith Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial.

一种新的抗PD-L1抗体作为单一治疗或联合靶向治疗晚期实体瘤的安全性和临床活性：PACT Ia/Ib期试验。

PatnaikA, Yap TA, Chung HC, de Miguel MJ, Bang YJ, Lin CC, Su WC, Italiano A, Chow KH,Szpurka AM, Yu D, Zhao Y, Carlsen M, Schmidt S, Vangerow B, Gandhi L, Xu X,Bendell J.

ClinCancer Res. 2021 Mar 1;27(5):1267-1277.

MEK-ingthe Most of It: Strategies to Co-target Gαq and MAPK in Uveal Melanoma.

MEK：葡萄膜黑色素瘤中Gαq和MAPK联合靶向的策略。

NeelatureSriramareddy S, Smalley KSM.

ClinCancer Res. 2021 Mar 1;27(5):1217-1219.

Vaccine-InducedIntratumoral Lymphoid Aggregates Correlate with Survival Following Treatmentwith a Neoadjuvant and Adjuvant Vaccine in Patients with Resectable PancreaticAdenocarcinoma.

在可切除胰腺癌患者中，疫苗诱导的瘤内淋巴聚集与新佐剂和佐剂疫苗治疗后的生存率相关。

ZhengL, Ding D, Edil BH, Judkins C, Durham JN, Thomas DL 2nd, Bever KM, Mo G, SoltSE, Hoare JA, Bhattacharya R, Zhu Q, Osipov A, Onner B, Purtell KA, Cai H,Parkinson R, Hacker-Prietz A, Herman JM, Le DT, Azad NS, De Jesus-Acosta AMC,Blair AB, Kim V, Soares KC, Manos L, Cameron JL, Makary MA, Weiss MJ, SchulickRD, He J, Wolfgang CL, Thompson ED, Anders RA, Sugar E, Jaffee EM, Laheru DA.

ClinCancer Res. 2021 Mar 1;27(5):1278-1286.

CEACAM7Is an Effective Target for CAR T-cell Therapy of Pancreatic DuctalAdenocarcinoma.

CEACAM7是治疗胰腺导管腺癌的有效靶点。

Raj D,Nikolaidi M, Garces I, Lorizio D, Castro NM, Caiafa SG, Moore K, Brown NF,Kocher HM, Duan X, Nelson BH, Lemoine NR, Marshall JF.

ClinCancer Res. 2021 Mar 1;27(5):1538-1552.

SelectedArticles from This Issue.

本期精选文章。

[Noauthors listed]

ClinCancer Res. 2021 Mar 1;27(5):1215.

TheOxford Classic Links Epithelial-to-Mesenchymal Transition to Immunosuppressionin Poor Prognosis Ovarian Cancers.

牛津经典将预后不良的卵巢癌的上皮间质转化与免疫抑制联系起来。

Hu Z,Cunnea P, Zhong Z, Lu H, Osagie OI, Campo L, Artibani M, Nixon K, Ploski J,Santana Gonzalez L, Alsaadi A, Wietek N, Damato S, Dhar S, Blagden SP, Yau C,Hester J, Albukhari A, Aboagye EO, Fotopoulou C, Ahmed A.

ClinCancer Res. 2021 Mar 1;27(5):1570-1579.

PlasmaTumor Mutation Burden and Response to Pembrolizumab-Response.

血浆肿瘤突变负荷和对Pembrolizumab反应的反应。

AggarwalC, Thompson JC, Carpenter EL.

ClinCancer Res. 2021 Mar 1;27(5):1581.

PlasmaTumor Mutation Burden and Response to Pembrolizumab-Letter.

血浆肿瘤突变负荷和对Pembrolizumab的反应。

Xue Z,Guo X, Wen J, Cai W, Xue X, Zhao X, Zhao J, Bai Y.

ClinCancer Res. 2021 Mar 1;27(5):1580.

Correction:A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary toHormone Receptor-positive Breast Cancer.

校正：阿贝美昔布治疗激素受体阳性乳腺癌继发脑转移患者的II期研究。

TolaneySM, Sahebjam S, Rhun EL, Bachelot T, Kabos P, Awada A, Yardley D, Chan A, ConteP, Diéras V, Lin NU, Bear M, Chapman SC, Yang Z, Chen Y, Anders CK.

ClinCancer Res. 2021 Mar 1;27(5):1582.

Clin Cancer Res[Jour] AND 27[volume] AND 6[issue]

临床癌症研究 27卷 6期

PARPInhibitors in Cancer Diagnosis and Therapy.

PARP抑制剂在肿瘤诊断和治疗中的应用。

ChanCY, Tan KV, Cornelissen B.

ClinCancer Res. 2021 Mar 15;27(6):1585-1594.

Delta-24-RGD,an Oncolytic Adenovirus, Increases Survival and Promotes Proinflammatory ImmuneLandscape Remodeling in Models of AT/RT and CNS-PNET.

Delta-24-RGD是一种溶瘤腺病毒，在AT/RT和CNS-PNET模型中增加存活率并促进促炎性免疫景观重塑。

Garcia-MoureM, Gonzalez-Huarriz M, Labiano S, Guruceaga E, Bandres E, Zalacain M, MarrodanL, de Andrea C, Villalba M, Martinez-Velez N, Laspidea V, Puigdelloses M,Gallego Perez-Larraya J, Iñigo-Marco I, Stripecke R, Chan JA, Raabe EH, Kool M,Gomez-Manzano C, Fueyo J, Patiño-García A, Alonso MM.

ClinCancer Res. 2021 Mar 15;27(6):1807-1820.

T-cell-engagingTherapy for Solid Tumors.

实体瘤的T细胞介入治疗。

deMiguel M, Umana P, Gomes de Morais AL, Moreno V, Calvo E.

ClinCancer Res. 2021 Mar 15;27(6):1595-1603.

ABlood-based Assay for Assessment of Tumor Mutational Burden in First-lineMetastatic NSCLC Treatment: Results from the MYSTIC Study.

一种基于血液的分析方法用于评估一线转移性NSCLC治疗中的肿瘤突变负荷：来自神秘研究的结果。

Si H,Kuziora M, Quinn KJ, Helman E, Ye J, Liu F, Scheuring U, Peters S, Rizvi NA,Brohawn PZ, Ranade K, Higgs BW, Banks KC, Chand VK, Raja R.

ClinCancer Res. 2021 Mar 15;27(6):1631-1640.

TissueHypoxia and Alterations in Microvascular Architecture Predict GlioblastomaRecurrence in Humans.

组织缺氧和微血管构筑改变可预测人类胶质母细胞瘤复发。

StadlbauerA, Kinfe TM, Eyüpoglu I, Zimmermann M, Kitzwögerer M, Podar K, Buchfelder M,Heinz G, Oberndorfer S, Marhold F.

ClinCancer Res. 2021 Mar 15;27(6):1641-1649.

UnbiasedDetection of Driver Mutations in Extramammary Paget Disease.

乳腺外Paget病驱动基因突变的无偏检测。

IshidaY, Kakiuchi N, Yoshida K, Inoue Y, Irie H, Kataoka TR, Hirata M, Funakoshi T,Matsushita S, Hata H, Uchi H, Yamamoto Y, Fujisawa Y, Fujimura T, Saiki R,Takeuchi K, Shiraishi Y, Chiba K, Tanaka H, Otsuka A, Miyano S, Kabashima K,Ogawa S.

ClinCancer Res. 2021 Mar 15;27(6):1756-1765.

BRCA2,ATM, and CDK12 Defects Differentially Shape Prostate Tumor Driver Genomics andClinical Aggression.

BRCA2、ATM和CDK12缺陷对前列腺肿瘤驱动基因和临床侵袭性有不同的影响。

WarnerE, Herberts C, Fu S, Yip S, Wong A, Wang G, Ritch E, Murtha AJ, VandekerkhoveG, Fonseca NM, Angeles A, Beigi A, Schönlau E, Beja K, Annala M, Khalaf D, ChiKN, Wyatt AW.

ClinCancer Res. 2021 Mar 15;27(6):1650-1662.

Attenuationof SRC Kinase Activity Augments PARP Inhibitor-mediated Synthetic Lethality inBRCA2-altered Prostate Tumors.

SRC激酶活性的减弱增强了PARP抑制剂介导的BRCA2改变前列腺肿瘤的合成致死率。

ChakrabortyG, Patail NK, Hirani R, Nandakumar S, Mazzu YZ, Yoshikawa Y, Atiq M, Jehane LE,Stopsack KH, Lee GM, Abida W, Morris MJ, Mucci LA, Danila D, Kantoff PW.

ClinCancer Res. 2021 Mar 15;27(6):1792-1806.

CombiningNeratinib with CDK4/6, mTOR, and MEK Inhibitors in Models of HER2-positiveCancer.

尼拉替尼联合CDK4/6、mTOR和MEK抑制剂治疗HER2阳性肿瘤模型。

ZhaoM, Scott S, Evans KW, Yuca E, Saridogan T, Zheng X, Wang H, Korkut A, Cruz PicoCX, Demirhan M, Kirby B, Kopetz S, Diala I, Lalani AS, Piha-Paul S,Meric-Bernstam F.

ClinCancer Res. 2021 Mar 15;27(6):1681-1694.

ARID1AMutation May Define an Immunologically Active Subgroup in Patients withMicrosatellite Stable Colorectal Cancer.

ARID1A突变可能定义微卫星稳定型结直肠癌患者的免疫活性亚群。

MehrvarzSarshekeh A, Alshenaifi J, Roszik J, Manyam GC, Advani SM, Katkhuda R, Verma A,Lam M, Willis J, Shen JP, Morris J, Davis JS, Loree JM, Lee HM, Ajani JA, MaruDM, Overman MJ, Kopetz S.

ClinCancer Res. 2021 Mar 15;27(6):1663-1670.

MesenchymalStem Cells Successfully Deliver Oncolytic Virotherapy to Diffuse IntrinsicPontine Glioma.

间充质干细胞成功地为弥漫性桥脑胶质瘤提供溶瘤病毒治疗。

ChastkofskyMI, Pituch KC, Katagi H, Zannikou M, Ilut L, Xiao T, Han Y, Sonabend AM, CurielDT, Bonner ER, Nazarian J, Horbinski CM, James CD, Saratsis AM, Hashizume R,Lesniak MS, Balyasnikova IV.

ClinCancer Res. 2021 Mar 15;27(6):1766-1777.

STK11/LKB1Mutations in NSCLC Are Associated with KEAP1/NRF2-Dependent RadiotherapyResistance Targetable by Glutaminase Inhibition.

NSCLC中STK11/LKB1突变与谷氨酰胺酶抑制靶向的KEAP1/NRF2依赖性放疗耐药相关。

SitthideatphaiboonP, Galan-Cobo A, Negrao MV, Qu X, Poteete A, Zhang F, Liu DD, Lewis WE, KempHN, Lewis J, Rinsurongkawong W, Giri U, Lee JJ, Zhang J, Roth JA, Swisher S,Heymach JV.

ClinCancer Res. 2021 Mar 15;27(6):1720-1733.

PhaseIB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLCFollowing Resistance to Initial EGFR Therapy (ETCTN 9903).

在对初始EGFR治疗产生耐药性后，Osimertinib联合Navitoclax治疗EGFR突变型NSCLC的IB期研究（ETCTN 9903）。

BertinoEM, Gentzler RD, Clifford S, Kolesar J, Muzikansky A, Haura EB, Piotrowska Z,Camidge DR, Stinchcombe TE, Hann C, Malhotra J, Villaruz LC, Paweletz CP, LauCL, Sholl L, Takebe N, Moscow JA, Shapiro GI, Jänne PA, Oxnard GR.

ClinCancer Res. 2021 Mar 15;27(6):1604-1611.

Neratinib-Plus-Cetuximabin Quadruple-WT (KRAS, NRAS, BRAF, PIK3CA) Metastatic Colorectal CancerResistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib Study.

尼拉替尼联合西妥昔单抗治疗对西妥昔单抗或帕尼单抗耐药的转移性结直肠癌：NSABP FC-7，一项Ib期研究。

JacobsSA, Lee JJ, George TJ, Wade JL 3rd, Stella PJ, Wang D, Sama AR, Piette F,Pogue-Geile KL, Kim RS, Gavin PG, Lipchik C, Feng H, Wang Y, Finnigan M, KieselBF, Beumer JH, Wolmark N, Lucas PC, Allegra CJ, Srinivasan A.

ClinCancer Res. 2021 Mar 15;27(6):1612-1622.

MolecularCharacterization and Therapeutic Targeting of Colorectal Cancers HarboringReceptor Tyrosine Kinase Fusions.

受体酪氨酸激酶融合结直肠癌的分子特征和治疗靶向性。

SinghH, Li YY, Spurr LF, Shinagare AB, Abhyankar R, Reilly E, Brais LK, Nag A, DucarMD, Thorner AR, Shapiro GI, Keller RB, Siletti C, Clark JW, Farago AF, Lin JJ,Demetri GD, Gujrathi R, Kulke MH, MacConaill LE, Ligon AH, Sicinska E, MeyersonML, Meyerhardt JA, Cherniack AD, Wolpin BM, Ng K, Giannakis M, Hornick JL,Cleary JM.

ClinCancer Res. 2021 Mar 15;27(6):1695-1705.

HAND1and BARX1 Act as Transcriptional and Anatomic Determinants of Malignancy inGastrointestinal Stromal Tumor.

HAND1和BARX1是胃肠道间质瘤恶性程度的转录和解剖决定因素。

HemmingML, Coy S, Lin JR, Andersen JL, Przybyl J, Mazzola E, Abdelhamid Ahmed AH, vande Rijn M, Sorger PK, Armstrong SA, Demetri GD, Santagata S.

ClinCancer Res. 2021 Mar 15;27(6):1706-1719.

InflammationMediates the Development of Aggressive Breast Cancer Following Radiotherapy.

炎症介导放疗后侵袭性乳腺癌的发展。

Ma L,Gonzalez-Junca A, Zheng Y, Ouyang H, Illa-Bochaca I, Horst KC, Krings G, WangY, Fernandez-Garcia I, Chou W, Barcellos-Hoff MH.

ClinCancer Res. 2021 Mar 15;27(6):1778-1791.

IntegratedMolecular Characterization of Fumarate Hydratase-deficient Renal Cell Carcinoma.

延胡索酸水合酶缺陷型肾细胞癌的综合分子特征。

Sun G,Zhang X, Liang J, Pan X, Zhu S, Liu Z, Armstrong CM, Chen J, Lin W, Liao B, LinT, Huang R, Zhang M, Zheng L, Yin X, Nie L, Shen P, Zhao J, Zhang H, Dai J,Shen Y, Li Z, Liu J, Chen J, Liu J, Wang Z, Zhu X, Ni Y, Qin D, Yang L, Chen Y,Wei Q, Li X, Zhou Q, Huang H, Yao J, Chen N, Zeng H.

ClinCancer Res. 2021 Mar 15;27(6):1734-1743.

RandomizedPhase II Trial of Sipuleucel-T with or without Radium-223 in Men withBone-metastatic Castration-resistant Prostate Cancer.

具有或不含镭223的西布列古-T治疗抗骨转移性去势前列腺癌的随机二期试验。

MarshallCH, Fu W, Wang H, Park JC, DeWeese TL, Tran PT, Song DY, King S, Afful M,Hurrelbrink J, Manogue C, Cotogno P, Moldawer NP, Barata PC, Drake CG, PosadasEM, Armstrong AJ, Sartor O, Antonarakis ES.

ClinCancer Res. 2021 Mar 15;27(6):1623-1630.

ABispecific Single-Domain Antibody Boosts Autologous Vγ9Vδ2-T Cell ResponsesToward CD1d in Chronic Lymphocytic Leukemia.

双特异性单域抗体促进慢性淋巴细胞白血病自体Vγ9Vδ2-T细胞对CD1d的应答。

deWeerdt I, Lameris R, Ruben JM, de Boer R, Kloosterman J, King LA, Levin MD,Parren PWHI, de Gruijl TD, Kater AP, van der Vliet HJ.

ClinCancer Res. 2021 Mar 15;27(6):1744-1755.

SelectedArticles from This Issue.

本期精选文章。

[Noauthors listed]

ClinCancer Res. 2021 Mar 15;27(6):1583.

Double-hitSignature with TP53 Abnormalities Predicts Poor Survival in Patients withGerminal Center Type Diffuse Large B-cell Lymphoma Treated with R-CHOP.

TP53异常的双重击中信号预示着用R-CHOP治疗的生发中心型弥漫性大B细胞淋巴瘤患者生存率低。

SongJY, Perry AM, Herrera AF, Chen L, Skrabek P, Nasr MR, Ottesen RA, Nikowitz J,Bedell V, Murata-Collins J, Li Y, McCarthy C, Pillai R, Wang J, Wu X, Zain J,Popplewell L, Kwak LW, Nademanee AP, Niland JC, Scott DW, Gong Q, Chan WC,Weisenburger DD.

ClinCancer Res. 2021 Mar 15;27(6):1671-1680.

Correction:A Randomized Controlled Trial of a 6-Month Low-Carbohydrate Intervention onDisease Progression in Men with Recurrent Prostate Cancer: Carbohydrate andProstate Study 2 (CAPS2).

纠正：一项随机对照试验，为期6个月的低碳水化合物干预治疗复发性前列腺癌患者的疾病进展：碳水化合物和前列腺研究2（CAPS2）。

FreedlandSJ, Allen J, Jarman A, Oyekunle T, Armstrong AJ, Moul JW, Sandler HM, PosadasE, Levin D, Wiggins E, Howard LE, Wu Y, Lin PH.

ClinCancer Res. 2021 Mar 15;27(6):1823.

JosephV. Simone: In Memoriam (1935-2021).

约瑟夫诉西蒙尼：《纪念》（1935-2021）。

DowningJR, Pui CH.

ClinCancer Res. 2021 Mar 15;27(6):1821-1822.

Clin Cancer Res[Jour] AND 27[volume] AND 7[issue]

临床癌症研究 27卷 7期

LXH254,a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for theTreatment of MAPK-Driven Tumors.

LXH254，一种有效和选择性的ARAF保护BRAF和CRAF抑制剂，用于治疗MAPK驱动的肿瘤。

MonacoKA, Delach S, Yuan J, Mishina Y, Fordjour P, Labrot E, McKay D, Guo R, HigginsS, Wang HQ, Liang J, Bui K, Green J, Aspesi P, Ambrose J, Mapa F, Griner L,Jaskelioff M, Fuller J, Crawford K, Pardee G, Widger S, Hammerman PS, EngelmanJA, Stuart DD, Cooke VG, Caponigro G.

ClinCancer Res. 2021 Apr 1;27(7):2061-2073.

FDAApproval Summary: Atezolizumab Plus Bevacizumab for the Treatment of Patientswith Advanced Unresectable or Metastatic Hepatocellular Carcinoma.

FDA批准摘要：阿替唑珠单抗联合贝伐单抗治疗晚期不能切除或转移性肝癌患者。

CasakSJ, Donoghue M, Fashoyin-Aje L, Jiang X, Rodriguez L, Shen YL, Xu Y, Jiang X,Liu J, Zhao H, Pierce WF, Mehta S, Goldberg KB, Theoret MR, Kluetz PG, PazdurR, Lemery SJ.

ClinCancer Res. 2021 Apr 1;27(7):1836-1841.

FDAApproval Summary: Accelerated Approval of Sacituzumab Govitecan-hziy forThird-line Treatment of Metastatic Triple-negative Breast Cancer.

FDA批准摘要：加速批准Sacituzumab-Govitecan-hziy用于转移性三阴性乳腺癌的三线治疗。

WahbyS, Fashoyin-Aje L, Osgood CL, Cheng J, Fiero MH, Zhang L, Tang S, Hamed SS,Song P, Charlab R, Dorff SE, Ricks TK, Barnett-Ringgold K, Dinin J, GoldbergKB, Theoret MR, Pazdur R, Amiri-Kordestani L, Beaver JA.

ClinCancer Res. 2021 Apr 1;27(7):1850-1854.

TargetingGermline- and Tumor-Associated Nucleotide Excision Repair Defects in Cancer.

靶向生殖系和肿瘤相关的核苷酸切除修复癌症的缺陷。

TopkaS, Steinsnyder Z, Ravichandran V, Tkachuk K, Kemel Y, Bandlamudi C, WinkelMadsen M, Furberg H, Ouerfelli O, Rudin CM, Iyer G, Lipkin SM, Mukherjee S,Solit DB, Berger MF, Bajorin DF, Rosenberg JE, Taylor BS, de Stanchina E, VijaiJ, Offit K.

ClinCancer Res. 2021 Apr 1;27(7):1997-2010.

PIPAC-OX:A Phase I Study of Oxaliplatin-Based Pressurized Intraperitoneal AerosolChemotherapy in Patients with Peritoneal Metastases.

PIPAC-OX：以奥沙利铂为基础的腹腔气雾剂加压化疗治疗腹膜转移患者的I期研究。

Kim G,Tan HL, Sundar R, Lieske B, Chee CE, Ho J, Shabbir A, Babak MV, Ang WH, Goh BC,Yong WP, Wang L, So JBY.

ClinCancer Res. 2021 Apr 1;27(7):1875-1881.

Efficacyof Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal JunctionCancer with Programmed Death Ligand 1 Combined Positive Score ≥10.

彭博罗珠单抗治疗晚期胃食管结癌的程序性死亡配体1联合阳性评分≥10。

WainbergZA, Fuchs CS, Tabernero J, Shitara K, Muro K, Van Cutsem E, Bang YJ, Chung HC,Yamaguchi K, Varga E, Chen JS, Hochhauser D, Thuss-Patience P, Al-Batran SE,Garrido M, Kher U, Shih CS, Shah S, Bhagia P, Chao J.

ClinCancer Res. 2021 Apr 1;27(7):1923-1931.

Identificationof a Synthetic Lethal Relationship between Nucleotide Excision Repair Deficiencyand Irofulven Sensitivity in Urothelial Cancer.

尿路上皮癌中核苷酸切除修复缺陷与伊洛芬敏感性之间的综合致死关系的鉴定。

BörcsökJ, Sztupinszki Z, Bekele R, Gao SP, Diossy M, Samant AS, Dillon KM, Tisza V,Spisák S, Rusz O, Csabai I, Pappot H, Frazier ZJ, Konieczkowski DJ, Liu D,Vasani N, Rodrigues JA, Solit DB, Hoffman-Censits JH, Plimack ER, Rosenberg JE,Lazaro JB, Taplin ME, Iyer G, Brunak S, Lozsa R, Van Allen EM, Szüts D, MouwKW, Szallasi Z.

ClinCancer Res. 2021 Apr 1;27(7):2011-2022.

VLA4-TargetedNanoparticles Hijack Cell Adhesion-Mediated Drug Resistance to TargetRefractory Myeloma Cells and Prolong Survival.

VLA4靶向纳米颗粒劫持细胞粘附介导的耐药目标难治性骨髓瘤细胞和延长生存。

FontanaF, Scott MJ, Allen JS, Yang X, Cui G, Pan D, Yanaba N, Fiala MA, O'Neal J,Schmieder-Atteberry AH, Ritchey J, Rettig M, Simons K, Fletcher S, Vij R,DiPersio JF, Lanza GM.

ClinCancer Res. 2021 Apr 1;27(7):1974-1986.

PhaseI Study of MK-4166, an Anti-human Glucocorticoid-Induced TNF Receptor Antibody,Alone or with Pembrolizumab in Advanced Solid Tumors.

抗人糖皮质激素诱导的肿瘤坏死因子受体抗体MK-4166单独或与Pembrolizumab联合治疗晚期实体瘤的Ⅰ期研究。

PapadopoulosKP, Autio K, Golan T, Dobrenkov K, Chartash E, Chen Q, Wnek R, Long GV.

ClinCancer Res. 2021 Apr 1;27(7):1904-1911.

PSA-TargetedAlpha-, Beta-, and Positron-Emitting Immunotheranostics in Murine ProstateCancer Models and Nonhuman Primates.

小鼠前列腺癌模型和非人灵长类动物的PSA靶向α、β和正电子放射免疫治疗。

VeachDR, Storey CM, Lückerath K, Braun K, von Bodman C, Lamminmäki U, Kalidindi T,Strand SE, Strand J, Altai M, Damoiseaux R, Zanzonico P, Benabdallah N, PankovD, Scher HI, Scardino P, Larson SM, Lilja H, McDevitt MR, Thorek DLJ, Ulmert D.

ClinCancer Res. 2021 Apr 1;27(7):2050-2060.

FDAApproval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive,HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer.

FDA批准摘要：阿贝利西联合富维司坦治疗HR阳性、HER2阴性、PIK3CA突变、晚期或转移性乳腺癌患者。

NarayanP, Prowell TM, Gao JJ, Fernandes LL, Li E, Jiang X, Qiu J, Fan J, Song P, Yu J,Zhang X, King-Kallimanis BL, Chen W, Ricks TK, Gong Y, Wang X, Windsor K, RhieuSY, Geiser G, Banerjee A, Chen X, Reyes Turcu F, Chatterjee DK, Pathak A,Seidman J, Ghosh S, Philip R, Goldberg KB, Kluetz PG, Tang S, Amiri-KordestaniL, Theoret MR, Pazdur R, Beaver JA.

ClinCancer Res. 2021 Apr 1;27(7):1842-1849.

PETImaging of TIGIT Expression on Tumor-Infiltrating Lymphocytes.

肿瘤浸润淋巴细胞TIGIT表达的PET显像。

ShafferT, Natarajan A, Gambhir SS.

ClinCancer Res. 2021 Apr 1;27(7):1932-1940.

A METTargeting Antibody-Drug Conjugate Overcomes Gemcitabine Resistance inPancreatic Cancer.

一种MET靶向抗体药物结合物克服了吉西他滨在胰腺癌中的耐药。

CazesA, Betancourt O, Esparza E, Mose ES, Jaquish D, Wong E, Wascher AA, Tiriac H,Gymnopoulos M, Lowy AM.

ClinCancer Res. 2021 Apr 1;27(7):2100-2110.

Morningfor Irofulven, What Could be fiNER?

Irofulven早上好，什么能成为fiNER？

JiangH, Greenberg RA.

ClinCancer Res. 2021 Apr 1;27(7):1833-1835.

ClinicalProteomics of Metastatic Melanoma Reveals Profiles of Organ Specificity andTreatment Resistance.

转移性黑色素瘤的临床蛋白质组学揭示了器官特异性和治疗耐药性。

BeckL, Harel M, Yu S, Markovits E, Boursi B, Markel G, Geiger T.

ClinCancer Res. 2021 Apr 1;27(7):2074-2086.

Atezolizumabplus Bevacizumab: A Novel Breakthrough in Hepatocellular Carcinoma.

阿替唑珠单抗联合贝伐单抗：肝细胞癌的新突破。

CastetF, Willoughby CE, Haber PK, Llovet JM.

ClinCancer Res. 2021 Apr 1;27(7):1827-1829.

PressurizedIntraperitoneal Aerosol Chemotherapy: The Road from Promise to Proof.

加压腹腔气雾剂化疗：从承诺到证明的道路。

deJong LAW, van Erp NP, Bijelic L.

ClinCancer Res. 2021 Apr 1;27(7):1830-1832.

Changesin Diffuse Optical Tomography Images During Early Stages of NeoadjuvantChemotherapy Correlate with Tumor Response in Different Breast Cancer Subtypes.

不同亚型乳腺癌新辅助化疗早期弥漫性光学断层扫描图像改变与肿瘤反应相关。

AltoeML, Kalinsky K, Marone A, Kim HK, Guo H, Hibshoosh H, Tejada M, Crew KD,Accordino MK, Trivedi MS, Hershman DL, Hielscher AH.

ClinCancer Res. 2021 Apr 1;27(7):1949-1957.

PhaseI Trial of DNA Methyltransferase Inhibitor Guadecitabine Combined withCisplatin and Gemcitabine for Solid Malignancies Including Urothelial Carcinoma(SPIRE).

DNA甲基转移酶抑制剂胍地西他滨联合顺铂和吉西他滨治疗包括尿路上皮癌（SPIRE）在内的实体恶性肿瘤的Ⅰ期试验。

CrabbSJ, Danson S, Catto JWF, Hussain S, Chan D, Dunkley D, Downs N, Marwood E, DayL, Saunders G, Light M, Whitehead A, Ellis D, Sarwar N, Enting D, Birtle A,Johnson B, Huddart R, Griffiths G.

ClinCancer Res. 2021 Apr 1;27(7):1882-1892.

SelectedArticles from This Issue.

本期精选文章。

[Noauthors listed]

ClinCancer Res. 2021 Apr 1;27(7):1825.

ImagingTumor-Infiltrating Lymphocytes in Brain Tumors with [64Cu]Cu-NOTA-anti-CD8 PET.

用[64Cu]Cu-NOTA-抗cd8pet显像脑肿瘤浸润淋巴细胞。

NagleVL, Henry KE, Hertz CAJ, Graham MS, Campos C, Parada LF, Pandit-Taskar N,Schietinger A, Mellinghoff IK, Lewis JS.

ClinCancer Res. 2021 Apr 1;27(7):1958-1966.

BaselineCirculating Tumor Cell Count as a Prognostic Marker of PSA Response and DiseaseProgression in Metastatic Castrate-Sensitive Prostate Cancer (SWOG S1216).

基线循环肿瘤细胞计数作为转移性去势敏感性前列腺癌PSA反应和疾病进展的预后标志物（SWOG S1216）。

GoldkornA, Tangen C, Plets M, Morrison GJ, Cunha A, Xu T, Pinski JK, Ingles SA, TricheT, Harzstark AL, Kohli M, MacVicar GR, Vaena DA, Crispino AW, McConkey DJ, LaraPN Jr, Hussain MHA, Quinn DI, Vogelzang NJ, Thompson IM Jr, Agarwal N.

ClinCancer Res. 2021 Apr 1;27(7):1967-1973.

PreclinicalEvaluation and Phase Ib Study of Prexasertib, a CHK1 Inhibitor, and Samotolisib(LY3023414), a Dual PI3K/mTOR Inhibitor.

CHK1抑制剂Prexasertib和PI3K/mTOR双抑制剂Samotolisib（LY3023414）的临床前评价和Ib期研究。

HongDS, Moore KN, Bendell JC, Karp DD, Wang JS, Ulahannan SV, Jones S, Wu W, DonohoGP, Ding Y, Capen A, Wang X, Bence Lin A, Patel MR.

ClinCancer Res. 2021 Apr 1;27(7):1864-1874.

PreclinicalModeling of Surgery and Steroid Therapy for Glioblastoma Reveals Changes inImmunophenotype that are Associated with Tumor Growth and Outcome.

胶质母细胞瘤手术和类固醇治疗的临床前模型揭示了与肿瘤生长和预后相关的免疫表型的变化。

OtvosB, Alban TJ, Grabowski MM, Bayik D, Mulkearns-Hubert EE, Radivoyevitch T,Rabljenovic A, Johnson S, Androjna C, Mohammadi AM, Barnett GH, Ahluwalia MS,Vogelbaum MA, Fecci PE, Lathia JD.

ClinCancer Res. 2021 Apr 1;27(7):2038-2049.

Inhibitionof Hedgehog Signaling Alters Fibroblast Composition in Pancreatic Cancer.

抑制Hedgehog信号改变胰腺癌成纤维细胞组成。

SteeleNG, Biffi G, Kemp SB, Zhang Y, Drouillard D, Syu L, Hao Y, Oni TE, Brosnan E,Elyada E, Doshi A, Hansma C, Espinoza C, Abbas A, The S, Irizarry-Negron V,Halbrook CJ, Franks NE, Hoffman MT, Brown K, Carpenter ES, Nwosu ZC, Johnson C,Lima F, Anderson MA, Park Y, Crawford HC, Lyssiotis CA, Frankel TL, Rao A,Bednar F, Dlugosz AA, Preall JB, Tuveson DA, Allen BL, Pasca di Magliano M.

ClinCancer Res. 2021 Apr 1;27(7):2023-2037.

RadiotherapyDelivered before CDK4/6 Inhibitors Mediates Superior Therapeutic Effects in ER+Breast Cancer.

CDK4/6抑制剂前放疗对ER+乳腺癌有较好的治疗效果。

PetroniG, Buqué A, Yamazaki T, Bloy N, Liberto MD, Chen-Kiang S, Formenti SC, GalluzziL.

ClinCancer Res. 2021 Apr 1;27(7):1855-1863.

PhaseIb Clinical Trial of IGV-001 for Patients with Newly Diagnosed Glioblastoma.

IGV-001治疗新诊断胶质母细胞瘤的Ib期临床试验。

AndrewsDW, Judy KD, Scott CB, Garcia S, Harshyne LA, Kenyon L, Talekar K, Flanders A,Atsina KB, Kim L, Martinez N, Shi W, Werner-Wasik M, Liu H, Prosniak M, CurtisM, Kean R, Ye DY, Bongiorno E, Sauma S, Exley MA, Pigott K, Hooper DC.

ClinCancer Res. 2021 Apr 1;27(7):1912-1922.

AbirateroneAcetate Induces CREB1 Phosphorylation and Enhances the Function of the CBP-p300Complex, Leading to Resistance in Prostate Cancer Cells.

醋酸阿比特龙诱导CREB1磷酸化并增强CBP-p300复合物的功能，导致前列腺癌细胞的耐药性。

Pan W,Zhang Z, Kimball H, Qu F, Berlind K, Stopsack KH, Lee GM, Choueiri TK, KantoffPW.

ClinCancer Res. 2021 Apr 1;27(7):2087-2099.

ClinicalResponsiveness to All-trans Retinoic Acid Is Potentiated by LSD1 Inhibition andAssociated with a Quiescent Transcriptome in Myeloid Malignancies.

在髓系恶性肿瘤中，LSD1抑制可增强对全反式维甲酸的临床反应性，并与静态转录组相关。

TayariMM, Santos HGD, Kwon D, Bradley TJ, Thomassen A, Chen C, Dinh Y, Perez A,Zelent A, Morey L, Cimmino L, Shiekhattar R, Swords RT, Watts JM.

ClinCancer Res. 2021 Apr 1;27(7):1893-1903.

InitialWhole-Genome Sequencing of Plasma Cell Neoplasms in First Responders andRecovery Workers Exposed to the World Trade Center Attack of September 11,2001.

2001年9月11日世贸中心袭击事件中急救人员和康复人员血浆细胞肿瘤的初步全基因组测序。

MauraF, Diamond B, Maclachlan KH, Derkach A, Yellapantula VD, Rustad EH, HultcrantzM, Shah UA, Hong J, Landau HJ, Iacobuzio-Donahue CA, Papaemmanuil E, Irby S,Crowley L, Crane M, Webber MP, Goldfarb DG, Zeig-Owens R, Giricz O, Verma A,Prezant DJ, Dogan A, Shah SP, Zhang Y, Landgren O.

ClinCancer Res. 2021 Apr 1;27(7):2111-2118.

Diffusion-weightedImaging Allows for Downgrading MR BI-RADS 4 Lesions in Contrast-enhanced MRI ofthe Breast to Avoid Unnecessary Biopsy.

扩散加权成像允许在乳腺增强MRI中降低MR BI-RADS 4个病灶的级别，以避免不必要的活检。

ClauserP, Krug B, Bickel H, Dietzel M, Pinker K, Neuhaus VF, Marino MA, Moschetta M,Troiano N, Helbich TH, Baltzer PAT.

ClinCancer Res. 2021 Apr 1;27(7):1941-1948.

BiomarkerDiscovery in Patients with Immunotherapy-Treated Melanoma with Imaging MassCytometry.

免疫治疗黑色素瘤的生物标志物的成像-质谱分析。

Martinez-MorillaS, Villarroel-Espindola F, Wong PF, Toki MI, Aung TN, Pelekanou V, Bourke-MartinB, Schalper KA, Kluger HM, Rimm DL.

ClinCancer Res. 2021 Apr 1;27(7):1987-1996.

Outcomesof Oral Vinorelbine in Progressive Desmoid Fibromatosis-Response.

口服长春瑞滨治疗进行性硬纤维瘤病的疗效。

Mir O,Honoré C, Chamseddine AN, Faron M, Haddag-Miliani L, Bayle A, Le Cesne A.

ClinCancer Res. 2021 Apr 1;27(7):2120.

Outcomesof Oral Vinorelbine in Progressive Desmoid Fibromatosis-Letter.

口服长春瑞滨治疗进行性硬纤维瘤病的疗效。

ZhengC, Min L, Tu C.

ClinCancer Res. 2021 Apr 1;27(7):2119.

Clin Cancer Res[Jour] AND 27[volume] AND 8[issue]

临床癌症研究 27卷 8期

FDAApproval Summary: Selpercatinib for the Treatment of Lung and Thyroid Cancerswith RET Gene Mutations or Fusions.

FDA批准摘要：Selpercatinib治疗RET基因突变或融合的肺癌和甲状腺癌。

BradfordD, Larkins E, Mushti SL, Rodriguez L, Skinner AM, Helms WS, Price LSL,Zirkelbach JF, Li Y, Liu J, Charlab R, Turcu FR, Liang D, Ghosh S, Roscoe D,Philip R, Zack-Taylor A, Tang S, Kluetz PG, Beaver JA, Pazdur R, Theoret MR,Singh H.

ClinCancer Res. 2021 Apr 15;27(8):2130-2135.

PhaseI Study of the CD47 Blocker TTI-621 in Patients with Relapsed or RefractoryHematologic Malignancies.

CD47阻滞剂TTI-621在复发或难治性血液病患者中的研究。

AnsellSM, Maris MB, Lesokhin AM, Chen RW, Flinn IW, Sawas A, Minden MD, Villa D,Percival MM, Advani AS, Foran JM, Horwitz SM, Mei MG, Zain J, Savage KJ,Querfeld C, Akilov OE, Johnson LDS, Catalano T, Petrova PS, Uger RA, SieversEL, Milea A, Roberge K, Shou Y, O'Connor OA.

ClinCancer Res. 2021 Apr 15;27(8):2190-2199.

FDAApproval Summary: Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Injection forSubcutaneous Use in Patients with HER2-positive Breast Cancer.

FDA批准摘要：Pertuzumab、Trastuzumab和透明质酸酶zzxf注射液用于HER2阳性乳腺癌患者的皮下注射。

GaoJJ, Osgood CL, Gong Y, Zhang H, Bloomquist EW, Jiang X, Qiu J, Yu J, Song P,Rahman NA, Chiu HJ, Ricks TK, Rizvi F, Hou S, Wilson W, Abukhdeir AM, SeidmanJ, Ghosh S, Philip R, Pierce WF, Bhatnagar V, Kluetz PG, Pazdur R, Beaver JA,Amiri-Kordestani L.

ClinCancer Res. 2021 Apr 15;27(8):2126-2129.

Emergenceof Enzalutamide Resistance in Prostate Cancer is Associated with BCL-2 and IKKBDependencies.

前列腺癌对恩扎鲁胺耐药的出现与BCL-2和IKKB依赖性有关。

LiangY, Jeganathan S, Marastoni S, Sharp A, Figueiredo I, Marcellus R, Mawson A,Shalev Z, Pesic A, Sweet J, Guo H, Uehling D, Gurel B, Neeb A, He HH,Montgomery B, Koritzinsky M, Oakes S, de Bono JS, Gleave M, Zoubeidi A, WoutersBG, Joshua AM.

ClinCancer Res. 2021 Apr 15;27(8):2340-2351.

TranscriptomicAnalysis of Laser Capture Microdissected Tumors Reveals Cancer- andStromal-Specific Molecular Subtypes of Pancreatic Ductal Adenocarcinoma.

激光捕获微解剖肿瘤的转录分析显示胰腺导管腺癌的癌细胞和基质特异性分子亚型。

BirnbaumDJ, Begg SKS, Finetti P, Vanderburg C, Kulkarni AS, Neyaz A, Hank T, Tai E,Deshpande V, Bertucci F, Birnbaum D, Lillemoe KD, Warshaw AL, Mino-Kenudson M,Fernandez-Del Castillo C, Ting DT, Liss AS.

ClinCancer Res. 2021 Apr 15;27(8):2314-2325.

Yap1Mediates Trametinib Resistance in Head and Neck Squamous Cell Carcinomas.

Yap1介导头颈部鳞状细胞癌对曲美替尼的耐药性。

MudiantoT, Campbell KM, Webb J, Zolkind P, Skidmore ZL, Riley R, Barnell EK, Ozgenc I,Giri T, Dunn GP, Adkins DR, Griffith M, Egloff AM, Griffith OL, Uppaluri R.

ClinCancer Res. 2021 Apr 15;27(8):2326-2339.

SelectedArticles from This Issue.

本期精选文章。

[Noauthors listed]

ClinCancer Res. 2021 Apr 15;27(8):2121.

Developmentand Validation of Machine Learning-based Model for the Prediction of Malignancyin Multiple Pulmonary Nodules: Analysis from Multicentric Cohorts.

基于机器学习的多发性肺结节恶性肿瘤预测模型的建立与验证：多中心队列分析。

ChenK, Nie Y, Park S, Zhang K, Zhang Y, Liu Y, Hui B, Zhou L, Wang X, Qi Q, Li H,Kang G, Huang Y, Chen Y, Liu J, Cui J, Li M, Park IK, Kang CH, Shen H, Yang Y,Guan T, Zhang Y, Yang F, Kim YT, Wang J.

ClinCancer Res. 2021 Apr 15;27(8):2255-2265.

ANovel Mouse Model of Radiation-Induced Cardiac Injury Reveals Biological andRadiological Biomarkers of Cardiac Dysfunction with Potential Clinical Relevance.

一种新的放射性心脏损伤小鼠模型揭示了具有潜在临床意义的心功能不全的生物学和放射学生物标志物。

DreyfussAD, Goia D, Shoniyozov K, Shewale SV, Velalopoulou A, Mazzoni S, Avgousti H,Metzler SD, Bravo PE, Feigenberg SJ, Ky B, Verginadis II, Koumenis C.

ClinCancer Res. 2021 Apr 15;27(8):2266-2276.

FollicularLymphoma-associated BTK Mutations are Inactivating Resulting in Augmented AKTActivation.

滤泡性淋巴瘤相关BTK突变失活导致AKT活化增强。

Hu N,Wang F, Sun T, Xu Z, Zhang J, Bernard D, Xu S, Wang S, Kaminski M, Devata S,Phillips T, Malek SN.

ClinCancer Res. 2021 Apr 15;27(8):2301-2313.

Regorafenib-AvelumabCombination in Patients with Microsatellite Stable Colorectal Cancer(REGOMUNE): A Single-arm, Open-label, Phase II Trial.

雷戈拉非尼-阿维鲁单抗联合治疗微卫星稳定型结直肠癌：一项单臂、开放标签、II期试验。

CousinS, Cantarel C, Guegan JP, Gomez-Roca C, Metges JP, Adenis A, Pernot S, BelleraC, Kind M, Auzanneau C, Le Loarer F, Soubeyran I, Bessede A, Italiano A.

ClinCancer Res. 2021 Apr 15;27(8):2139-2147.

TreatmentOutcomes and Clinical Characteristics of Patients with KRAS-G12C-Mutant Non-SmallCell Lung Cancer.

KRAS-G12C突变型非小细胞肺癌患者的治疗结果和临床特征。

ArbourKC, Rizvi H, Plodkowski AJ, Hellmann MD, Knezevic A, Heller G, Yu HA, LadanyiM, Kris MG, Arcila ME, Rudin CM, Lito P, Riely GJ.

ClinCancer Res. 2021 Apr 15;27(8):2209-2215.

TranscriptomicProfiling Identifies a Risk Stratification Signature for Predicting PeritonealRecurrence and Micrometastasis in Gastric Cancer.

转录组分析确定了预测胃癌腹膜复发和微转移的危险分层特征。

LeeIS, Lee H, Hur H, Kanda M, Yook JH, Kim BS, Woo Y, Kodera Y, Kim K, Goel A.

ClinCancer Res. 2021 Apr 15;27(8):2292-2300.

GeneExpression-Based Prediction of Neoadjuvant Chemotherapy Response in EarlyBreast Cancer: Results of the Prospective Multicenter EXPRESSION Trial.

基于基因表达预测早期乳腺癌新辅助化疗反应：前瞻性多中心表达试验的结果。

EdlundK, Madjar K, Lebrecht A, Aktas B, Pilch H, Hoffmann G, Hofmann M, Kolberg HC,Boehm D, Battista M, Seehase M, Stewen K, Gebhard S, Cadenas C, Marchan R,Brenner W, Hasenburg A, Koelbl H, Solbach C, Gehrmann M, Tanner B, Weber KE,Loibl S, Sachinidis A, Rahnenführer J, Schmidt M, Hengstler JG.

ClinCancer Res. 2021 Apr 15;27(8):2148-2158.

TherapeuticImplications of Detecting MAPK-Activating Alterations in Cutaneous and UnknownPrimary Melanomas.

检测皮肤和未知原发性黑色素瘤中MAPK激活改变的治疗意义。

ShoushtariAN, Chatila WK, Arora A, Sanchez-Vega F, Kantheti HS, Rojas Zamalloa JA,Krieger P, Callahan MK, Betof Warner A, Postow MA, Momtaz P, Nair S, Ariyan CE,Barker CA, Brady MS, Coit DG, Rosen N, Chapman PB, Busam KJ, Solit DB, PanageasKS, Wolchok JD, Schultz N.

ClinCancer Res. 2021 Apr 15;27(8):2226-2235.

PhaseII Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapyin Patients with Mismatch Repair-proficient Metastatic Colorectal Cancer.

Durvalumab和Tremelimumab联合放疗治疗错配修复熟练的转移性结直肠癌的Ⅱ期单臂研究。

SegalNH, Cercek A, Ku G, Wu AJ, Rimner A, Khalil DN, Reidy-Lagunes D, Cuaron J, YangTJ, Weiser MR, Romesser PB, Stadler ZK, Varghese AM, Ganesh K, Yaeger R,Connell LC, Faleck D, Abou-Alfa GK, Mcauliffe KC, Vaiskauskas P, Solter ML,Ogle M, Adamow MJ, Holland A, Vedantam P, Wong P, Merghoub T, Vakiani E,Hollmann TJ, Juluru K, Chou JF, Capanu M, Erinjeri J, Solomon S, Yamada Y,Kemeny N, Crane CH, Saltz LB.

ClinCancer Res. 2021 Apr 15;27(8):2200-2208.

Alterationsin BAP1 Are Associated with Cisplatin Resistance through Inhibition ofApoptosis in Malignant Pleural Mesothelioma.

BAP1的改变通过抑制恶性胸膜间皮瘤细胞凋亡与顺铂耐药相关。

OehlK, Vrugt B, Wagner U, Kirschner MB, Meerang M, Weder W, Felley-Bosco E,Wollscheid B, Bankov K, Demes MC, Opitz I, Wild PJ.

ClinCancer Res. 2021 Apr 15;27(8):2277-2291.

MicrobiomeAnalysis of More Than 2,000 NHS Bowel Cancer Screening Programme Samples Showsthe Potential to Improve Screening Accuracy.

对2000多个NHS肠癌筛查项目样本的微生物组分析显示，有可能提高筛查准确性。

YoungC, Wood HM, Fuentes Balaguer A, Bottomley D, Gallop N, Wilkinson L, Benton SC,Brealey M, John C, Burtonwood C, Thompson KN, Yan Y, Barrett JH, Morris EJA,Huttenhower C, Quirke P.

ClinCancer Res. 2021 Apr 15;27(8):2246-2254.

Developmentand Multiple Validation of the Protein Multi-marker Panel for Diagnosis ofPancreatic Cancer.

胰腺癌诊断蛋白多标记物组的建立及多重验证。

Kim Y,Yeo I, Huh I, Kim J, Han D, Jang JY, Kim Y.

ClinCancer Res. 2021 Apr 15;27(8):2236-2245.

BlockingTIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study ofLY3321367 with or without an Anti-PD-L1 Antibody.

阻断TIM-3治疗难治性晚期实体瘤：LY3321367加或不加抗PD-L1抗体的Ia/b期研究。

HardingJJ, Moreno V, Bang YJ, Hong MH, Patnaik A, Trigo J, Szpurka AM, Yamamoto N, DoiT, Fu S, Calderon B, Velez de Mendizabal N, Calvo E, Yu D, Gandhi L, Liu ZT,Galvao VR, Leow CC, de Miguel MJ.

ClinCancer Res. 2021 Apr 15;27(8):2168-2178.

ImprovedDetection of Postoperative Residual Meningioma with [68Ga]Ga-DOTA-TOC PETImaging Using a High-resolution Research Tomograph PET Scanner.

使用高分辨率研究断层扫描PET扫描仪对[68Ga]Ga-DOTA-TOC-PET成像术后残留脑膜瘤的检测。

BashirA, Larsen VA, Ziebell M, Fugleholm K, Law I.

ClinCancer Res. 2021 Apr 15;27(8):2216-2225.

Long-TermFollow-up of a Phase III Study of ch14.18 (Dinutuximab) + CytokineImmunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032.

ch14.18（地诺妥昔单抗）+细胞因子免疫治疗高危神经母细胞瘤儿童的III期研究的长期随访：COG研究ANBL0032。

Yu AL,Gilman AL, Ozkaynak MF, Naranjo A, Diccianni MB, Gan J, Hank JA, Batova A,London WB, Tenney SC, Smith M, Shulkin BL, Parisi M, Matthay KK, Cohn SL, MarisJM, Bagatell R, Park JR, Sondel PM.

ClinCancer Res. 2021 Apr 15;27(8):2179-2189.

DualAntiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, inFirst-line Treatment of Metastatic Colorectal Cancer: Results of a Phase IIStudy.

双抗血管生成药物贝伐单抗联合曲巴尼在转移性结直肠癌一线治疗中的应用：一项II期研究的结果。

MooiJ, Chionh F, Savas P, Da Gama Duarte J, Chong G, Brown S, Wong R, Price TJ,Wann A, Skrinos E, Mariadason JM, Tebbutt NC.

ClinCancer Res. 2021 Apr 15;27(8):2159-2167.

TargetingDNA Damage Repair Functions of Two Histone Deacetylases, HDAC8 and SIRT6,Sensitizes Acute Myeloid Leukemia to NAMPT Inhibition.

以两种组蛋白去乙酰化酶HDAC8和SIRT6的DNA损伤修复功能为靶点，使急性髓系白血病对NAMPT抑制敏感。

ZhangP, Brinton LT, Williams K, Sher S, Orwick S, Tzung-Huei L, Mims AS, Coss CC,Kulp SK, Youssef Y, Chan WK, Mitchell S, Mustonen A, Cannon M, Phillips H,Lehman AM, Kauffman T, Beaver L, Canfield D, Grieselhuber NR, Alinari L,Sampath D, Yan P, Byrd JC, Blachly JS, Lapalombella R.

ClinCancer Res. 2021 Apr 15;27(8):2352-2366.

HowDid We Get a COVID-19 Vaccine in Less Than 1 Year?

我们是如何在不到一年的时间内获得COVID-19疫苗的？

WherryEJ, Jaffee EM, Warren N, D'Souza G, Ribas A; AACR COVID-19 and Cancer TaskForce.

ClinCancer Res. 2021 Apr 15;27(8):2136-2138.

AMoving Target: Inactivating BTK Mutations as Drivers of Follicular Lymphoma.

一个移动目标：灭活BTK突变作为促卵泡淋巴瘤的驱动因素。

AfaghaniJ, Taylor J.

ClinCancer Res. 2021 Apr 15;27(8):2123-2125.